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Q U I L L  O N  S C A L P E L  This section
provides a medium through which Canadian 
surgeons can declare themselves, briefly and in­
formally, on the day-to-day affairs of surgery.
IMMUNOLOGY AND CANCER
In the past decade various studies in pa­
tients with cancer have greatly advanced our 
knowledge of basic immunology. Now there 
is some suggestion that this knowledge may 
contribute to the treatment of such patients. 
In this issue of the Journal (page 12) Proc­
tor, Lewis and Mansell give an overview of 
present and potential modalities of immuno­
therapy.
The live antituberculosis vaccine, bacille 
Calmette Guerin (BCG), which has been 
widely studied in animals, has, since the 
mid-1960s, shown suggestive immunothera- 
peutic potential in man; presumably it acts 
as a nonspecific stimulator of cellular im­
munity or macrophage activity. Canada is 
in the forefront of randomized clinical trials 
of this agent in bronchogenic carcinoma 
and malignant melanoma, and these trials 
should establish whether this agent has a 
place in cancer treatment. Using retro­
spective control groups, Morton and Gutter- 
man in the United States, as well as some 
Canadian groups, have carried out trials that 
strongly suggest that BCG therapy can pro­
long remission in cases of advanced malig­
nant melanoma. There is, however, no doubt 
that extensive surgical extirpation of the 
cancer is vitally important before immuno­
therapy can have any effect. And, to estab­
lish the usefulness of immunotherapy, ran­
domized trials are necessary because retro­
spective control studies may be invalidated 
by advances in surgical and chemothera­
peutic management or changes in the nature 
of the disease.
In cases of acute myeloid leukemia there 
seems little doubt that nonspecific immune 
stimulation can prolong remission. Both live 
BCG and its methanol extractable residue 
(MER) greatly increase the duration of re­
mission and survival, but the role of specific
leukemic cell vaccines is still not clear. Ma­
lignant cells, usually irradiated and treated 
in various ways in an attempt to enhance 
immunogenicity, have appeared to improve 
survival in bronchogenic carcinoma as well 
as leukemia, but they may only be acting 
as nonspecific stimulants to immunity. Tu­
mour-specific immunity in man is very dif­
ficult to measure by the present techniques. 
Variables such as the BCG strain, dosage, 
viability of organisms, and route of admin­
istration make it difficult to compare one 
clinical trial with another.
Even if immunologic manipulation cannot 
achieve tumour rejection there is little doubt 
that the state of the immune system in a 
patient with cancer is an important progno­
stic indicator. Immunocompetence may be 
measured by skin tests against recall anti­
gens such as purified protein derivative 
(PPD) or mumps, new antigens such as dini- 
trochlorobenzene (DNCB) or in-vitro stimu­
lation of lymphocytes by nonspecific mito­
gens such as phytohemagglutinin. Even a 
simple test such as the total lymphocyte 
count has some prognostic value. Several 
investigators have shown that a patient’s 
prognosis can be predicted by reference to 
immunologic parameters even when these 
are studied independently from traditional 
factors such as age, sex, histologic features 
of the tumour and extent of disease.
Debate continues about the simplest and 
best parameters to study, but some day 
these will be used to stratify patients going 
into trials of new forms of surgical treat­
ment or adjuvant chemotherapy.
Although immunotherapy must remain 
experimental, the place of immunodiagnosis 
is continually gaining importance. Radio­
immunoassays of hormones such as calci­
tonin and parathormone not only can con-
10 THE CANADIAN JOURNAL OF SURGERY Vol. 19
firm the diagnosis of a tumour but also, 
when coupled with selective venous cannu- 
lation, can help the surgeon localize the 
lesion. Carcinoembryonic antigen may aid 
in the diagnosis of gastrointestinal cancer, 
and it is already being used to detect early 
recurrence in prospective trials of adjuvant 
chemotherapy for carcinoma of the gastroin­
testinal tract, lung and breast. The diagnosis 
and chemotherapeutic management of gesta­
tional neoplasms (female choriocarcinomas) 
and testicular tumours depends greatly on 
the radioimmunoassay of the serum hor­
mones LH and HCG. And in some parts of 
the world (Russia and tropical Africa), the 
early detection of alpha-fetoprotein in a
patient’s serum can lead to the discovery of 
a primary hepatoma while it is still surgical­
ly curable.
In November 1975 the New York Acad­
emy of Sciences held a meeting on the im­
munobiology and immunotherapy of can­
cer. The published proceedings of this meet­
ing will review much of the basic knowledge 
in this area, but there is obviously still much 
to be learned. The immunologist has gained 
a prominent place in cancer investigation 
and is now establishing a role in the man­
agement of the cancer patient.
P. B. M cC ulloch , MD, FRCP[C]
McMaster University,
Hamilton, Ont.
SELF-ASSESSMENT
SESAP II QUESTION
317. Which of the following statements concerning sutures made from polyglycolic acid 
(Dexon) is/are correct?
(1) Absorption is complete within 60 days
(2) They have less tensile strength than cotton and silk sutures
(3) They are absorbed by hydrolysis rather than proteolysis
(4) They are weakened if infection develops
For this question one or more of the answers given above is correct. Your answer should 
be:
A if only 1, 2 and 3 are correct,
B if only 1 and 3 are correct,
C if only 2 and 4 are correct,
D if only 4 is correct,
E if all are correct.
For the critique of Ttem 317 see page 80 of this issue.
(Reproduced by permission of the American College of Surgeons from SESAP II Sylla­
bus: Surgical Education and Self-assessment Program No. 2.)
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Hepalean
...most frequently ordered anticoagulant in Canada
Hepalean Heparin Sodium U.S.P.
for injection... used for an ever increasing 
number of indications1 — thromboembolism, 
lung embolism, coronary heart disease, renal 
disease and hemodialysis, obstetrics, and as 
a concomitant drug in many areas, “ . . .an 
extremely effective drug for the manage­
ment of thrombosis. Properly given, it rapidly 
and reliably arrests thrombosis and prevents 
embolization, especially on the venous side 
of the circulation”2
In an international trial of heparin for low- 
dose prophylaxis involving 4121 patients3 
“sixteen deaths in the control and two in the
heparin group were ascribed to acute mas­
sive pu l mona ry  embol i sm (P<0.0024).” 
“Taking all pulmonary emboli together, the 
finding of a four fold reduction (22 vs. five) 
was also significant (P< 0.005).”
"Thus the final link in establishing the valid­
ity of low-dose heparin prophylaxis for post­
operative venous thromboembolism for 
those at high risk after general abdomino­
thoracic surgical procedures has been pro­
vided.” “ (5000 units at eight or 12 hours daily 
given subcutaneously and referred to as low- 
dose heparin)”4
Contraindications: Conditions with bleeding tendencies, hemophilia 
and severe clotting disorders; shock, hypersensitivity to heparin, 
severe liver damage.
Precautions: Large doses should be delayed four hours post-operative- 
ly. Use with caution during pregnancy and postpartum. Use with 
caution in patients with allergy. Long term use should be monitored 
for the possible development of osteoporosis.
Adverse Effects: Hypersensitivity reactions.
Hepalean Dosage and Administration: Parenteral. The following 
amounts, indicated by prothrombin time determinations. Usual adult 
dose; Intravenous, 10,000 U.S.P. Heparin Units initially, then 5,000-
10,000 units 4-6 times a day; Infusion, 20,000 to 40,000 units per litre 
at a rate of 15-30 units per minute. Subcutaneous, 10,000 to 20,000 
units initially, then 8,000 to 10,000 units 3 times a day. Usual pediatric 
dose, intravenous infusion, 50 units per kg of body weight initially, 
followed by 100 units per kg, or 3333 units per square metre of body 
surface 6 times a day.
Reference: 1. Heparin: Recent Abstracts of the Biomedical Litera­
ture, Excerpta Medica, 1975.
2. Edward Genton M .D., Guidelines for Heparin Therapy, 
Annals of Internal Medicine 80:77-82,1974.
3. Kakkar V .V . Corrigan TP, Fossard DP; Prevention of 
fatal postoperative pulmonary embolism by low doses of 
heparin: an international multicentre trial. Lancet 2:45-51, 
1975.
4. Sherry S., “ Low Dose Heparin Prophylaxis for Post­
operative VenousThromboembolism’’ NewEnglandJour- 
nal of M edicine 293 No. 6:300-302,1975.
For full prescribing information, see package insert.
Harris Laboratories
Brantford, Canada.
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REVIEW  ARTICLE
IMMUNOTHERAPY FOR CANCER: AN OVERVIEW*
J. W. PROCTOR, MB, BS, PhD, M. G. LEWIS, MD, FRCPath(Eng) and P. W. MANSELL, MA, MB, BCh, FRCS(Eng)t
Summary: Immunotherapy of cancer is of in­
terest to oncologists because it is specifically 
directed to cancer cells, sparing normal cells. 
While it is ineffective in most patients, espe­
cially those with widespread metastatic disease, 
it occasionally produces good results. Each of 
the available methods has inherent problems 
and, recently, attempts have been made to over­
come some of these. There is a strong case 
for small-scale experimental trials in highly se­
lected groups of patients who are intensively 
investigated for their immunologic status in 
relation to their tumour. Despite the lack of 
success in general, immunotherapy still appears 
to have a future as an adjunct to existing ther­
apy in order to control as much as to cure 
residual tumour.
Resume: L'immunotherapie du cancer interesse 
les oncologistes, parce que cette methode com­
bat directement les cellules cancereuses, tout 
en epargnant les cellules normales. Bien qu'elle 
soit inefficace chez la plupart des cancereux, 
surtout chez ceux porteurs de metastases eten- 
dues, elle donne parfois de bons resultats. 
Toutes les methodes anticancereuses ont leurs 
inconvenients propres et, dernierement, on a 
tente de surmonter certains de ces inconve­
nients. II y a la un champ interessant pour des 
essais experimentaux sur une echelie reduite, 
chez des groupes de malades qui sont actuelle- 
ment etudies quant a leur statut immunologique 
en regard de leur tumeur. Malgre I'absence 
generate de succes, l'immunotherapie semble 
encore assure d’un certain avenir, ne fut-ce que 
comme un adjuvant des traitements existants, 
ou elle pourrait enrayer et meme guerir des 
tumeurs residuelles.
fections. These first attempts in humans 
were based on the observations that animals 
exposed to a tumour rejected a subsequent 
challenge, probably through a reaction 
against the then unrecognized group of his- 
toincompatibility antigens rather than 
against tumour-specific antigens, since the 
animals used were outbred.
Although occasional cases of objective 
regression occurred in these early series, 
Woglom1 in 1929 concluded his survey of 
tumour immunology by stating, “Nothing 
may be hoped for at present in respect to a 
successful therapy in this direction.”
A n t it u m o u r  I m m u n it y
Gross- in 1943, Lewis and Aptekman3 
in 1951 and other, later workers demon­
strated the existence of “tumour-specific 
antigens” in inbred animal systems. It was 
then found that human patients mounted 
immunologically specific reactions against 
a variety of cancers, which led to the re­
cent upsurge of interest in immunotherapy.
Both cellular and humoral factors and 
combinations of the two probably consti­
tute effector mechanisms against tumours 
(Fig. 1). Most of these mechanisms have 
been worked out in vitro and their use has 
been reviewed by Berkelhammer.4 By fol­
lowing the course of a patient sequentially 
and quantitating the various indices, several
T h e  concept of stimulating and augmenting 
antitumour immune responses in the treat­
ment of human cancer arose in the last 2 
decades of the 19th century and followed 
the recognition of immunity to bacterial in-
*From McGill University cancer research unit, McGill University, Montreal, Que.
tDepartment o f oncology, Royal Victoria Hos­pital, Montreal.
Reprint requests to: Dr. J. W. Proctor, McGill University cancer research unit, 3655 Drummond St., Montreal, PQ H3G 1Y6.
Fig. L -  Presumed effector mechanisms in anti­tumour immunity, c =  cellular mechanism, h =  humoral mechanism.
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Fie 2 -Representation ot events occurring ai stages m lumuui f —
conceptual, but is based on data obtained in studies of tumours in animals and in man.
workers have been able to make satisfactory 
correlations with the stage and even the his­
tologic type of tumour.5'8
The series of events taking place during 
the various stages in tumour progression is 
represented in Fig. 2. Although largely con­
ceptual the schema is based on data ob­
tained in studies of a variety of tumours in 
animals and in man. The course of events 
can be summarized as follows:
1. During growth of the primary tumour 
it is likely that there is a lag period before 
immunity is initiated by the presentation of 
tumour antigen to the local draining lymph 
nodes; however, what governs the length 
of the lag period is not known.
2. Chronic persistent antigenic stimula­
tion, as is the case in tumour development, 
then leads to a “paralysis” of the draining 
lymph nodes and a decrease in the number 
of sensitized cells released from these 
lymph nodes.0
3. At the same time, the increasing con­
centration of antigen in the blood may 
neutralize antitumour antibody10 and an 
apparent state of nonreactivity develops be­
fore metastases become clinically detect­
able,5 though whether this actually leads to 
metastatic spread or the metastatic spread 
itself results in a state of nonreactivity is 
not yet established.
4. Removal of the primary tumour in 
animals leads to “unblocking” of the para­
lyzed lymph nodes0 and, even in the pres­
ence of metastases, to a decrease in blood 
antigen concentrations associated with a 
rise in humoral antibody titres10 and re­
storation of detectable immunity in the 
blood (J. W. Proctor, unpublished observa­
tions).
5. The further growth of metastases ul­
timately leads to a second disappearance 
of detectable immunity before the meta­
stases are detected clinically.11
Place and T iming of Im m unotherapy
Even though immunotherapy has no place 
in the treatment of resectable primary tu­
mours, it may be useful in the treatment of 
residual tumours after surgical treatment, 
chemotherapy or radiotherapy, or in com­
bination therapy regimens. Immunotherapy
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is most efficacious shortly after operation, 
when the mass of residual tumour is small­
est and when there is a natural increase in 
the patient’s immune activity. This does not 
exclude immunotherapy later, as lymph 
nodes draining areas away from those af­
fected by secondary tumour are not neces­
sarily maximally stimulated at this time 
and, theoretically, could be boosted with 
a suitably placed injection of antigen. Nor 
is there any reason to suppose that there is 
any limit to the amount of tumour that 
may be destroyed by a persistent effective 
immune response, though this in itself may 
be difficult to achieve. Further, when chem­
otherapy must be discontinued because of 
side effects and when the tumour mass has 
been sufficiently diminished there is un­
doubtedly a place for immunotherapy, when 
the immunocompetence of the patient is 
being reestablished.
Why do Tumours Grow Despite 
an I mmune R esponse?
When one is considering the problem 
confronting the would-be immunotherapist, 
it is worth remembering that, although tu­
mour-specific immunologic reactions are 
frequently detected in patients with cancer, 
the cancer almost always progresses relent­
lessly and often eventually kills the patient. 
Thus the clinician must hope to succeed 
where nature herself has failed.
The reasons for the failure of defence 
mechanisms that in vitro often appear to 
function adequately are probably numerous 
and extremely complex; but there is no 
doubt that, if they could be unravelled suf­
ficiently, a more rational approach to aug­
menting immune responses would follow.
Among the possible reasons for this fail­
ure, the existence of immunologically me­
diated blocking phenomena” 1- that prevent 
immunologic killing of tumour cells ranks 
as one of the most likely explanations. 
These phenomena include antibody, 13-15 
antigensN and antigen/antibody complex­
es3- 10 and are postulated to act variously 
on the afferent, the central, or the efferent 
limbs of an immune response, or on all of 
these. The objective of immunotherapy 
should be to boost the immunologically cy­
totoxic mechanisms without increasing the 
so-called blocking mechanisms, and this
target itself presents a major problem: there 
is a theoretical possibility that, for instance, 
immunizing a patient with his own tumour 
cells may augment either the cytotoxic or 
the blocking mechanisms.
I mmunocompetence of the Patient
This discussion has considered specific 
immunologic effects and has not taken into 
account the further problem confronting the 
immunotherapist: in the absence of immu­
nosuppressive measures, such as chemother­
apy and radiotherapy, there may be a pro­
found decrease in immunocompetence to un­
related as well as previously unencountered 
antigens. This has been a controversial is­
sue and, though there is no doubt that with 
terminal malignant disease, as with advanced 
tuberculosis, there is an overall debilitation 
including that affecting the immune system, 
there is increasing evidence that in a num­
ber of cancers generalized immunoincom- 
petence precedes terminal illness17- 13 and 
can even occur quite early in the disease. 
Of interest, therefore, is the finding that, 
in the presence of anergy to skin sensitizing 
agents and common nontumour antigens, 
immunization with a tumour or with a non­
specific adjuvant can provoke a shortlived 
but readily detectable specific reaction. 19 
Thus, when one considers immunologic 
status it is necessary to distinguish between 
general immunocompetence with regard to 
nontumour antigens and specific compe­
tence against the tumour.
Immunotherapy in Animals 
and Man
Although immunoprophylaxis (immuniza­
tion preceding an injection of tumour cells) 
has been easy to achieve in animal models, 
immunotherapy (immunization designed to 
cause regression of existing tumours) has 
been rather more difficult, and has been 
only possible at all while tumours are still 
lelatively small.-’0- 21 The immunogenicity 
(the capacity for a tumour to provoke an 
immune response) has proved important in 
immunotherapy in animal models;22- 23 in 
general, the more highly immunogenic, the 
greater the success.
The detailed historical aspects of immu­
notherapy in humans, well reviewed by Cur­
rie, 24 will not be discussed in this paper.
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Specific immunization
Category of 
immunotherapy
Components 
of therapy
Potential
problems
Nonspecific
immunization
Active Syngeneic /  allogeneic attenuated tumour cells
Facilitation Neutralization on repeated injection
Adjuvants(bacterial, chemical)
Cellular(adoptive)
1. Allogeneic/xenogeneiclymphocytes2. Extracts from com­ponents of 1 , e. g., transfer factor, im­mune RNA
Graft-versus-host disease None known
Allogeneic lymphocytes
Serum(passive)
1. Allogeneic/xenogeneic/ Anaphylaxis, serumsyngeneic antibody sickness
2. Ctmrponents of 1 linked Blocking substancesto radiotherapeutic andchemotherapeutic
agents
Allogeneic/xenogeneic properdin, interferon, humoral recognition factor, reagin
l l l d l L d U )  p i u u i v  tthe available methods will be summarized 
and a brief account of the rather recent 
practical steps being taken to circumvent 
such problems will be presented.In general, although occasional patients 
have benefited from most of the forms of 
therapy the majority of such patients have 
manifested no evidence of objective regres­
sion.The available methods for immunother­
apy, many of which were being attempted 
before 1920, are summarized in Table I.
Active Therapy
Specific immunization.—The use of live 
tumour cells is associated with the potential 
risk of active tumour growth and, with few 
exceptions, most workers have used either 
killed or attenuated vaccines. Most com­
monly irradiated tumour cells are used, but 
recently it now appears that treatment of 
cells with mitomycin C, glutaraldehyde, iodo- 
acetate, or neuraminidase produces more 
satisfactory preparations. Neuraminidase 
has been shown in several systems to in­
crease the immunogenicity of tumour cells, 
probably by means of digestion of sialic 
acid residues in the glycocalyx of the cells 
rendering antigenic determinants more 
available.25A potential problem of this form ot 
therapy is raised by the finding in animals 
that spontaneous blood-borne metastatic 
spread may be facilitated or suppressed26'28 
after autoimmunization, depending on the
L U U I U U I  o i t - v  ---- ---------  -  ^used for immunization. Apart from Risley s 
series29 we do not know of any reported 
case of clinical deterioration following auto­
vaccination and, in our own experience of 
treating more than 75 patients, we have not 
even suspected that this might have occur­
red. One must remember, however, that 
most patients so treated had advanced dis­
ease and by definition a poor prognosis. It 
is unlikely that facilitation of tumour spread 
or growth would have been noticed in light 
of the fact that further growth and spread 
usually occurs relatively rapidly in such pa­
tients, irrespective of treatment.
Nonspecific immunization.— A number 
of adjuvants, including bacterial vaccines, 
some chemical compounds, and fractions of 
them, produce a nonspecific stimulation of 
the reticuloendothelial system and aug­
ment humoral and cellular responses to un­
related antigens. Of these agents, BCG (ba- 
cille Calmette Guerin) is best known,30' 31 
though much data are available for other 
agents such as Corynebacterium parvum ,32 
C. granulosum , 3 3  polyinosinic-polycytidylic 
acid,34 zymosan and its derivative glucan,,>J 
levamisole30 and Triton W .R ."1 in animal 
models. No one agent has been compared 
definitively to another, so that at present 
little may be said of their relative merits. 
Most of them have been shown to be ef­
fective in some animal systems and inef­
fective in others.In general, these agents act nonspecifical- 
ly by stimulating the reticuloendothelial sys-
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tem and by augmenting specific antitumour 
reactions. The latter supposedly might re­
sult from macrophage-mediated mechan­
isms, including better processing of tumour 
antigens for lymphocyte stimulation, more 
active clearance of abrogating antigen-an­
tibody complexes from the blood, or the 
provision of more specifically armed or non- 
specifically activated cytotoxic antitumour 
macrophages.
There are indications that, as in the case 
of specific active immunization, the dose is 
important,88' 89 as is the time point89 41 in 
the disease at which these agents are admin­
istered, and also the route of administra­
tion.49- 41 The activity of BCG has been 
shown to be greater after intravenous or in- 
traperitoneal administration to animals;40' 41 
and whether or not this should hold true 
for agents such as glucan in man may 
determine which of these many agents will 
be preferred by clinicians. Serious side ef­
fects have been reported after intradermal 
and, particularly, intratumoural injection of 
BCG,4 - and obviously the incidence of sys­
temic infection is likely to increase follow­
ing intravenous or intraperitoneal injection. 
Of interest, therefore, are the attempts to 
use C. parvum intravenously reported by 
Israel and Edelstein,43 and separately used 
by Woodruff and colleagues (Ghaffar, per­
sonal communication, 1974), apparently 
with only very transient (less than 24 hours) 
side effects including fever and malaise.
A further theoretical drawback to the 
use of the bacterial agents is that they are 
all highly immunogenic. Their repeated use 
could produce an increasingly rapid and ef­
fective antiadjuvant immune response,24 
which would neutralize the adjuvant before 
it stimulates the reticuloendothelial system 
to any great extent. Thus, it may be neces­
sary to have a large selection of such agents, 
which could be used sequentially.
Adoptive Therapy
Specific immunization. —  Lymphocytes 
are widely regarded as constituting a major 
effector mechanism in the rejection of skin 
grafts, and thus of solid tumours in the 
form of the delayed hypersensitivity reac­
tion. This type of immunity can be trans­
ferred adoptively by injection of sensitized 
lymphocytes in normal individuals.44- 45
The strength of any reactions mounted 
against a tumour after cross-immunization 
and cross-transfer of lymphocytes is more 
likely to be related to the degree of histo- 
incompatibility than to tumour antigens. If 
reactions are to be successful, it is likely that 
a generalized graft-versus-host (GVH) re­
action would have to be mounted and the 
advantages of suffering from this form of 
disease rather than cancer are dubious, to 
say the least. A failure to mount a GVH 
reaction, on the other hand, would probably 
result from rejection of the foreign lympho­
cytes, which would immediately nullify any 
beneficial effects they might have produced 
had they survived.
Two further forms of adoptive immuno­
therapy warrant close attention, both in­
volving cell-free extracts of lymphocytes. 
One can readily appreciate that the disad­
vantages of using whole allogeneic or xeno­
geneic lymphocytes, which can cause un­
wanted side effects of GVH reactions or 
which will be destroyed by an intact im­
mune response in the recipient, are poten­
tially overcome by using such extracts. The 
first of these other forms of therapy is use 
of transfer factor, a dialyzable extract of 
peripheral blood lymphocytes that can 
specifically transfer delayed hypersensitivity 
reactions (cellular immunity) in man and 
some animals.4«' 47 The second is the use 
of RNA extracts from sensitized lympho­
cytes demonstrated to convert nonimmune 
lymphocytes to specific immunologic activ­
ity, both in vitro48 and in vivo.49
This work has led to therapeutic attempts 
in a small number of cancer patients47’ 49 
and, though insufficient time has elapsed to 
permit one to make only the most tentative 
conclusions, there is no doubt that these 
approaches are promising. Recently, quanti­
ties of transfer factor have been produced 
from selected lymphoblastoid cell lines in 
tissue culture following stimulation with 
small amounts of transfer factor (Viza, per­
sonal communication, 1975). This enrich­
ment procedure will facilitate production of 
transfer factor from sera obtained from pa­
tients during early stages of the disease for 
treatment should they become immunoin- 
competent later on. It obviates the need for 
cross-immunization of patients or the use of 
animal products and can be achieved with-
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out greatly depleting the patients of a neces­
sary component of their immune defence 
against the tumour.
Nonspecific immunization.—As with the 
use of sensitized lymphocytes, there is 
little evidence that this form of therapy has 
been successful on its own. The problems 
inherent in specific adoptive therapy apply 
to nonspecific therapy, and it is doubtful 
whether this form of therapy has any po­
tential advantages over specific therapy.
Passive Therapy
Specific immunization.— One of the ear­
liest forms of therapy, the use of im­
mune serum has not proved particularly suc­
cessful. Recently, in animals50"52 and in 
man—in two cases of melanoma53' 54—  
antiserum linked to chemotherapeutic or ra- 
diotherapeutic agents was associated with 
tumour regression. Results of work in ani­
mals is increasingly promising, though all 
reports concern xenogeneic or allogeneic an­
tisera. The problem of administering serum 
from one species to another is that natural 
antibodies to the immunoglobulin of the 
species used for obtaining the antiserum 
may be present in the recipient, and it can 
be expected that the antiserum may be de­
stroyed relatively rapidly, particularly with 
repeated injection. With repeated therapy 
there is a potential risk of serum sickness 
or anaphylaxis,53 and the possibility of the 
putatively bad effects of blocking antibody 
has to be considered.
The use of autogenous antisera obtained 
at an early stage of the disease linked to 
radiotherapeutic or chemotherapeutic agents 
is practical and would obviate the potential 
problems associated with the use of xeno­
geneic antisera.
Nonspecific immunization.— A number 
of humoral substances, including reagin and 
properdin are present in so-called normal 
sera, some of which might act nonspecific- 
ally to augment the immune response. A 
factor present in normal serum humoral 
recognition factor (HRF) has been observed 
to disappear prior to the leukemic phase in 
an animal leukemia grown as a solid tumour 
(Di Luzio, personal communication, 1975). 
It crosses species barriers and, experimental­
ly, appears to be important in allowing full 
function of the reticuloendothelial system.
The early results from assaying cancer pa­
tients indicate that serum concentrations of 
HRF are low,55 and there may be a case 
in the future for treatment with fresh pre­
parations of the substance.
Nonspecific passive therapy so far has 
not been used to any great extent.
Therapy to Remove Blocking Substances
It is theoretically possible to remove 
blocking substances by passing blood through 
either antigen- or antibody-containing col­
umns or plates as a form of hemodialysis; 
the technologic base for this is essentially 
available already.56 However, until it can 
be established whether antigen itself, anti- 
gen/antibody complexes, “enhancing” anti­
body or antiantibody57' 58 are present in 
each patient and actively blocking immun­
ity, this approach must remain a hope.
Conclusions
The status of immunotherapy remains ill 
defined and most patients with cancer do 
not benefit from any of the many approach­
es available. However, throughout the 80- 
year history of immunotherapy the occa­
sional objective remission has been the rule 
in most series and such remission, con­
sidered with the unarguable success en­
countered in many animal systems, pro­
vides evidence that these forms of treatment 
can be successful.
What in fact can immunotherapy offer 
in relation to the more conventional modes 
of therapy? Surgical procedures have and 
probably always will hold the prime posi­
tion in the treatment of accessible solid 
tumours. Chemotherapy and radiotherapy 
alone or in combination have produced re­
markable effects in some forms of cancer, 
particularly those of the lymphoreticular 
system, and have proved most useful as an 
adjunct to surgical procedures in the treat­
ment of metastatic disease. Chemotherapy 
and radiotherapy make use of semiquan- 
titative differences between normal and neo­
plastic cells and thus tend to destroy sensi­
tive and often vital normal tissue. The great 
potential value of immunotherapy is that 
it distinguishes between normal and neo­
plastic tissue, specifically destroying tu­
mour cells and sparing the normal cells.
The immune system is complex. The re-
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cent rapid increase in our knowledge of its 
role in neoplasia, still far from complete, 
has served to confuse as much as clarify 
the issues. The value of multiple in-vitro 
tests has not been firmly established, as 
correlations with the stage of disease have 
been made only infrequently. Without a full 
understanding of the process it is unlikely 
that it will be possible to repair adequately 
what is, after all, a defective antitumour 
mechanism. If, as studies of animal models 
suggest, the number of irradiated tumour 
cells or the dose of an adjuvant such as 
BCG, is critical in clinical practice, then 
for a single patient who has, for example, a 
primary melanoma with a prognosis rang­
ing from only 6 months to as long as 15 
years, the chances of guessing correctly cer­
tainly are slim.
The best approach for clinicians at pres­
ent is to select from a number of different 
regimens one that is based on results ob­
tained in other patients who have had dis­
ease, the features of which closely resemble 
those in a particular patient, but this is 
feasible in only a few types of cancer.
A clinical success without any monitor­
ing of immunologic indices merely keeps us 
at the same point as that of the clinicians 
of 50 years ago and is unlikely to benefit 
future patients. There is no reason to sup­
pose that exactly the same course of ther­
apy will benefit the next or most of the 
succeeding patients who will be more or 
less immunocompetent with greater or 
smaller amounts of residual tumour. The 
treatment of diabetes with insulin produced 
both bad and good results until the meas­
urement of blood sugar and electrolyte con­
centrations became routinely available.
Thus, there is an urgent need to establish 
which of the many in-vitro tests are of value 
in assessing the status of the host-tumour 
relationship, establishing prognoses and per­
mitting the early detection of recurrence. 
This could be greatly aided by the investiga­
tion of patients undergoing immunotherapy, 
as changes in an immunologic index asso­
ciated with an objective remission are like­
ly to be highly significant.
However, these investigations are time- 
consuming and costly and require highly 
trained personnel. They are not practical 
in the large numbers of cases required for
relatively large-scale clinical trials.
These issues seem necessarily to militate 
against large-scale trials in most types of 
cancer, and probably only those trials in­
volving homogeneous classes of patients 
with a poor prognosis receiving conventional 
therapy are justified or indeed will yield 
results that can be readily analyzed in a 
reasonable period.
Therefore there seems to be a case for 
rather short-term, small-scale, perhaps even 
uncontrolled trials of therapy in a few pa­
tients. There would be a poor chance of a 
statistically significant result, but detailed 
sequential monitoring of many immunologic 
indices could be carried out. Regimens could 
be altered relatively frequently and could 
be based on observations of measured in­
creases or decreases in the levels of immu­
nologic indices providing a more rational 
approach to what is, after all, a highly am­
bitious endeavour.
Results from such small trials could be 
applied in setting up more formal, larger 
trials in the future. The emphasis in the 
past has been on providing a cure and, 
while this is still the ultimate goal, it is less 
realistic than that of controlling residual tu­
mour—one does not cure chronic heart 
failure, hypertension, or diabetes, but the 
control of these diseases is undeniably suc­
cessful. The numerous reports of patients 
with cancer who, often without any treat­
ment apart from surgical removal of the 
primary tumour, live free of symptoms for 
years before succumbing to their disease 
support the concept that control is a prac­
tical possibility.
Immunotherapy is unlikely ever to pro­
vide the sole answer to any cancer. It may 
well have a place as an adjunct to other 
forms of therapy; perhaps the keynote at 
present should be cautious optimism.
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an emerging problem.
“Bacteroides species are often over­
looked as a cause of serious infec­
tion both by clinicians and micro­
biologists. They are most commonly 
associated with intra-abdominal 
and pelvic sepsis following gastro­
intestinal surgery.”
“Our experience with this series of seriously 
ill patients provides clinical confirmation to 
complement recent in vitro evidence that '  
clindamycin is the antibiotic of choice for 
use in bacteroides infections. Not only was;* 
the response in 17 of the 18 patients favour­
able, but in several it was dramatic.”
Tracy, 0 .,e t al.(29 Jan.’72). 
Brit. med.J.,p. 280.
Haldane, E. V. and van Rooyen,C.E. (1972). 
C.M.A.J.,p. 1177.
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CAS INUSITE DE KYSTE HYDATIQUE OPERE*
L. DONTIGNY, MD, FRCS[C], C. MERCIER, MD, A. PAGE, MD, R. LEVY, MD, 
R. COSSETTE, MD, FRCS[C], C. PELLETIER, MD, FRCS[C] et 
A. VERDANT, MD, FRCS[C]
Resume: Presentation d'un cas inusite d’echino- 
coccose originant de la rate avec extension 
trans-diaphragmatique au poumon, chez une pa- 
tiente grecque ayant vecu sur une ferme d'ele- 
vage de moutons. Ouelques points essentiels 
sont releves sur I'epidemiologie, les elements 
diagnostiques et le traitement de cette maiadie.
Summary: A hydatid cyst of the spleen devel­
oped in a Greek-Canadian woman who had lived 
on a sheep farm. The cyst extended through the 
diaphragm to the left lower lobe. Splenectomy 
and left lower lobectomy and excision of con­
tiguous diaphragm were performed. Histopatho­
logic examination confirmed the presence of 
hydatid cysts in both spleen and lung. Postoper­
ative course was uneventful. In Canada hydatid 
disease is rare and its occurrence sporadic. It 
is commoner among Canadian Indians and im­
migrants than native Canadians. Treatment is 
surgical; en bloc excision of tissue eliminates 
the possibility of anaphylaxis or dissemination 
of scolices.
L ’echinococcose humaine parmi la popu­
lation autochtone du Canada demeure une 
rarete, mais l’inimigration en constitue une 
nouvelle source croissante. C’est le cas de 
notre patiente d’origine grecque qui presen­
te une atteinte primitive de la rate avec 
extension pulmonaire trans-phrenique.
H istoire de cas
Une patiente de 60 ans, nee en Grece et 
immigree au Canada depuis plusieurs annees, 
consultait une premiere fois a l’Hopital du 
Sacre-Coeur de Montreal pour troubles gyne- 
cologiques, et une radiographie pulmonaire de 
routine revelait une image suspecte a la base 
gauche (fig. 1). L’investigation bronchoscopi- 
que et bronchographique permettait d’exclure 
une atteinte pulmonaire. Au pneumoperitoine, 
la rate apparaissait calcifiee et fixee au dome
*Travail du service de chirurgie cardio-vasculaire 
et thoracique, departement de Chirurgie, Hopital 
du Sacre-Coeur de Montreal, Montreal, Que.
Les demandes de tires-a-part doivent etre addres­
sees a: L. Dontigny, md, Service de chirurgie 
cardio-vasculaire et thoracique, Departement de 
chirurgie, Hopital du Sacre-Coeur de Montreal, 
5400, ouest blvd Gouin, Montreal, PQ H4J 1C5. 
diaphragmatique. Le diagnostic d’echinococco-
se de la rate n’a pas ete precise, mais devant 
cette lesion asymptomatique et d’aspect non 
evolutif, aucun traitement n’a ete suggere.
Dix-huit mois plus tard, la patiente est ad- 
mise de nouveau en vue d’une hysterectomie 
pour metrorragies et l’image initiale notee sur 
la radiographie du poumon a nettement pro- 
gresse (fig. 2). Le pneumoperitoine est repete 
et laisse apercevoir la meme lesion de la rate 
qui est calcifiee et adherente au diaphragme 
mais qui semble maintenant deborder au-dela 
de celui-ci (fig. 3). Par ailleurs, la bronchogra- 
phie nous permet de deceler la presence de ni- 
veaux hydroaeriques a la peripherie du lobe 
inferieur gauche, un processus actif a ce 
niveau (fig. 4). Cette zone correspond a l’ima- 
ge deja mise en evidence sur les cliches sim­
ples et semble egalement fixee au diaphragme 
sous-jacent. Le diagnostic de maiadie hydati- 
que a depart splenique est maintenant soup- 
gonne. La patiente demeure asymptomatique, 
avec une formule sanguine normale sauf une 
eosinophylie controlee a 9%. Devant cette le­
sion evolutive, malgre un tableau clinique 
tout-a-fait silencieux, une thoracotomie postero- 
laterale gauche a ete pratiquee. II s’agissait ef- 
fectivement d’une lesion “en sablier” originant 
de la rate, avec envahissement pulmonaire a 
travers le diaphragme. La lesion a ete resequee 
en bloc par voie thoracique, comprenant la 
splenectomie, l’exerese d’une collerette dia­
phragmatique en continuite avec la lobectomie 
inferieure gauche. L’examen histopathologique 
confirmait le diagnostic par la presence de 
plusieurs kystes hydatiques dans la rate et le 
poumon. Devolution post-operatoire fut sans 
incident.
D iscussion
La maiadie hydatique causee par l’echi- 
nocoque granulosus se retrouve de fagon 
endemique particulierement dans les con- 
trees d’elevage de moutons, avec en fete 
PAmerique du Sud, l’Australie, la Nouvelle- 
Zelande et les pays du pourtour Mediteran- 
neen. Elle y presente un cycle dit domesti- 
que, alors qu’au Canada le meme parasite 
est vehicule par un cycle sylvestre1 et la 
maiadie est relativement rare et de nature 
sporadique. Une etude canadienne extensive 
sur le sujet revelait que la tres grande ma-
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Fig. 1.—Image peripherique arrondie a la base Fig. 2 .-L ’image a nettement progresse.
gauche.
Fig. 3.—La rate presente des calcifications; elle Fig. 4.—Bronchographie montra une image hy- 
est fixee au diaphragme de meme qu’au poumon droaerique en Peripherie du lobe inferieur gau- 
adjacent. che.
i
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jorite des 162 cas rapportes etaient des 
Indiens, vivant dans l’Ouest du pays.2’ 3 
Aucun cas dans cette serie n’etait rapporte 
au Quebec et ce n’est qu’en 1956 que Begin, 
Guy et Raymond,4 publiaient deux cas, ope- 
res a l’Hopital du Sacre-Coeur de Montreal; 
tous deux venaient de l’Abitibi. Par contre, 
de plus en plus de cas sont retrouves parmi 
notre population immigrants, sur 35 cas 
rapportes a Toronto en 1963, 29 venaient 
de pays infestes par le parasite; un bon nom- 
bre etaient Italiens.5
Le kyste hydatique primitif et isole de 
la rate est egalement rare; lors d’une etude 
autopsique, Deve6 donnait une incidence 
de 2.3% . Par ailleurs, l’atteinte pulmonaire 
que l’on rencontre, isolee ou non, est habi- 
tuellement primitive et l’extension directe 
de la maladie a travers le diaphragme, par- 
ticulierement a point de depart splenique, 
est une evolution tres atypique en soi.
Comme elements diagnostiques, nous re­
tenons principalement les sources epidemio- 
logiques bien caracteristiques. A la radio- 
graphie, les calcifications de la rate a la lu- 
miere d’une reactivation du processus, sug- 
gerent une lesion de nature inflammatoire; 
le tableau clinique est nettement en faveur 
d’une lesion benigne et les images pulmo- 
naires demeurent compatibles avec une at-
teinte kystique. L’eosinophylie a 9% opte 
pour une parasitose. Les divers tests biolo- 
giques suggeres, incluant l’intradermoreac- 
tion de Casoni, n’ont pas ete faits.
Le traitement de l’echinococcose consti­
tute demeure chirurgical; certains cas parti- 
culiers pourront parfois beneficier d’une 
approche non-chirurgical.7 L’exerese en bloc 
est le traitement de choix de fagon a eviter 
la contamination per-operatoire, eliminant 
ainsi la possibilite d’anaphylaxie ou d’ense- 
mencement de scolex.
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PRIMARY CARCINOMA OF THE GALLBLADDER: 
STUDY OF 108 CASES*
P. F. RICHARD, MD, FRCSf and J. CANTIN, MD, FRCS[C], FACSlj;
Summary: From 1948 through 1970, 108 cases 
of primary carcinoma of the gallbladder were 
recorded out of a total of 17 698 cases of 
cancer exclusive of skin cancer (incidence, 
0.6%). This review indicated that the following 
are the chief features of this condition: Primary 
gallbladder carcinoma is mainly a disease of 
women older than 60 years; abdominal pain oc­
curs in most patients and jaundice in more than 
half, and weight loss is also common; labora­
tory and radiographic features are nonspecific; 
the diagnosis is made or strongly suspected in 
only one-quarter and, moreover, in many patients 
the disease may not be discovered until patho­
logic examination is conducted postoperatively. 
Resection was possible in 41 of the 93 patients 
who underwent operation but treatment was 
conservative because it was palliative in 20, 
and in 20 of the other 21 who underwent chole­
cystectomy the disease was not recognized at 
operation. Overall, the 5-year survival rate was 
6.4%; for those who underwent curative resec­
tion it was 33%; and for patients without visible 
metastases at operation the mean survival was 
3 years. Improvement in survival will come from 
more frequent recognition of the cancer at 
operation so that an operation more adequate 
than cholecystectomy may be performed; that 
is, cholecystectomy, wedge resection of liver 
and resection of regional lymph nodes.
Resume: Sur un total de 17 698 cas de cancer 
de tous genres, sauf les cancers cutanes, nous 
avons releve, de 1948 a 1970, 108 cas de car- 
cinome primaire de la vesicule biliaire (fre­
quence, 0.6%). La presente revue a permis de 
preciser les caracteres principaux de cette pa- 
thologie: le carcinome primaire de la vesicule 
biliaire frappe, avant tout, des femmes de plus 
de 60 ans; une douleur abdominale est presente 
chez la majorite des malades et I'ictere chez 
plus de la moitie; I'amaigrissement est chose 
courante; les examens de laboratoire et les 
radiographies n'offrent rien de specifique. Le
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fFormerly resident in surgery, Hotel-Dieu Hos­
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Reprint requests to: Dr. Jacques Cantin, Depart­
ment of surgery, Hotel-Dieu Hospital, 3840 St. 
Urbain, Montreal, PQ H2W 1T8.
diagnostic n'est pose ou fortement soupconne 
que chez moins d'un quart des malades, a tel 
point que, dans nombre de cas, la maladie n'est 
decouverte qu'a I'occasion d'un examen patho- 
logique postoperatoire. Chez 41 des 93 malades 
operes, on a pratique la resection mais ce traite- 
ment a ete conservateur, n’ayant constitue qu'un 
palliatif chez 20 malades. Chez 20 des 21 autres 
patients qui ont subi une cholecystectomie, le 
carcinome n'a meme pas ete decele lors de 
I'operation. Dans I'ensemble, le taux de survie 
de 5 ans a ete de 6.4%, tandis que chez les 
malades oil la resection avait un caractere cura- 
tif, la survie a ete de 33%. Quant aux malades 
dont les metastases eventuelles n'etaient pas 
visibles lors de I'operation, la survie moyenne 
n'a pas depasse 3 ans. La prolongation de la 
survie ne deviendra une realite que par une 
identification plus frequente du cancer lors de 
I’intervention, celle-ci pouvant alors etre pra- 
tiquee d’une faqon differente et plus appropriee 
que la simple cholecystectomie, comportant, 
outre celle-ci, la resection cuneiforme du foie 
et la resection des ganglions lymphatiques 
regionaux.
F ir st  described in 1771 by de Stoll, pri­
mary carcinoma of the gallbladder still 
carries a poor prognosis.1 The silent pro­
gression of this cancer, without signs or 
symptoms, has made early diagnosis for­
tuitous. Usually, it is diagnosed during ex­
ploratory laparotomy, and resection is not 
attempted— either because the disease is 
extensive or because most surgeons are 
discouraged by the poor prognosis of the 
disease and do not wish to treat it aggres­
sively. However, knowledge of its natural 
history is necessary in view of the frequency 
of gallbladder operations and of the pro­
gressively increasing age of the population. 
We have therefore studied our experience 
with primary carcinoma of the gallbladder.
I n c id e n c e
From 1948 to 1970 inclusive, 108 cases 
of primary malignant neoplasms of the gall­
bladder were recorded in the tumour registry 
of Hotel-Dieu Hospital, Montreal. These 
cases were drawn from a total of 17 698 
cases of cancer (exclusive of skin), of which 
517 originated in the hepatobiliary-pancrea-
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TABLE I.—Age and Sex D istribution
Sex
Age ---------------------------
(yr) Male Female
40 - 49 ......................... 4 2
50 - 59 ......................... 0 11
60 - 6 9 ......................... 11 40
70 - 79 ......................... 6 26
80 - 8 9 ......................... 1 7
Total...........  22 (20%) 86 (80%)
tic tract. The incidence of primary carci­
noma of the gallbladder was, therefore, 
0.6% of all cancers (exclusive of skin) and 
20.8% of cancers arising in the hepatobili­
ary-pancreatic area. During the last 5 years 
of this study, 3237 cholecystectomies were 
performed and 26 cancers of the gallbladder 
diagnosed; carcinoma was thus encountered 
in a little less than 1 % (0.8%) of operations 
on the gallbladder.
Clinical Details, Results of
Investigations and Diagnosis
Clinical Details
Age and sex distribution of patients re­
vealed that carcinoma of the gallbladder was 
predominantly a disease of women (80%) 
of an older age group (84% over 60 years 
of age) (Table I).
The symptoms and signs and their in­
cidence are summarized in Table II. Ab­
dominal pain was the most frequent com­
plaint; in 42 patients it was the only symp­
tom and in 46 it was accompanied by jaun­
dice. Pain was of four types (Table II).
TABLE II.—Symptoms and Signs
No. (and %) 
of patients
Symptom or sign (n = 108)
Abdominal pain................................. 91 (84)
Biliary colic....................................  40 (37)
Chronic cholecystitis..................... 29 (27)
Acute cholecystitis....................  11 (10)
Vague upper abdominal pain.. 11 (10)
Jaundice..............................................  57 (52)
With abdominal pain...............  46 (42)
Without abdominal pain.........  11 (10)
General symptoms
Nausea........................................  70 (65)
Weight loss (>  4.5 kg)........... 68 (63)
Anorexia...................................... 59 (55)
Vomiting.....................................  42 (39)
Melena.............................................. 8 (7)
Asymptomatic.........................................  2 (2)
Jaundice was noted in more than half of the 
patients. Weight loss (>  4.5 kg) was noted 
by 68 patients and was a predominant 
finding.
Physical examination revealed hepato­
megaly alone in 28 patients and hepato­
megaly with an associated right upper quad­
rant mass in 26. Ascites was noted in 20, 
a mass in the right upper quadrant in 14.
Laboratory Findings
Anemia (Hb <  10 g/di) was noted in 
32 patients and leukocytosis (>  10 x 10!'/Z) 
in 41. Features of extrahepatic obstruction 
were usually noted in jaundiced patients.
Radiographic Findings
Cholangiographic (oral or intravenous) 
findings were abnormal in 64 patients: in 
24, stones were seen and in 40, a nonopaci- 
fied gallbladder was visualized. A barium 
meal was given to 72 patients: in 17 it 
showed compression and narrowing at the 
level of the antroduodenal area. Barium 
enema examination was performed in seven 
patients, in one of whom compression of 
the hepatic flexure was visualized. Selective 
celiac angiography was performed once; it 
showed the typical “champagne-glass” de­
formity (wide separation of the branches of 
the cystic artery with an associated tumour 
staining).
Diagnosis
Diagnosis was made or strongly suspected 
before operation in 20 patients and at opera­
tion or autopsy in 68. The diagnosis was 
made postoperatively by the pathologist in 
20 patients; with these patients, the surgeon 
had been unaware during the operation of 
the presence of cancer.
Treatment
An operation was performed in only 93 
of the 108 patients (Table III). Resection
TABLE III.—T reatment
Operative 
status and 
treatment
No. of patients 
(and % of 
total)
(n = 108)
% of patients 
with 
operable 
condition
Operability 93 (86) _
Resectability 41 (38) 44
Palliative 20 (18.5) 21.5
Curative 21 (19.5) 22.5
No treatment 15 (14) —
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TABLE IV.—T ype of Operations
Operative status and type
oj operation No. of patients
Resectable..................................
Cholecystectomy................
Cholecystectomy,
choledochotomy.............
Cholecystectomy +  biliary
diversion.........................
Nonresectable............................
Biopsy alone.......................
Biopsy cholecystostomy 
Biopsy -f biliary diversion 
Biopsy +  gastro­
enterostomy ....................
was possible in 41, with a view to cure in 
21 and palliation in 20. The types of opera­
tions are enumerated in Table IV. Because 
in the case of 20 of the 21 patients who 
had undergone curative resections the sur­
geon did not learn until after the operation 
that he had resected a carcinoma of the gall­
bladder, the treatment in this group was 
conservative: no liver resections were done.
Pathologic F indings
Histologic Features and Associated
Lesions
Most tumours were adenocarcinomas with 
a few squamous cell carcinomas and adeno- 
acanthomas (Table V). The site of origin 
could be ascertained in only a few cases, 
and was evenly distributed between the 
fundus, body and neck. Stones were found 
in 90 patients (83%) and were absent in 1, 
though in this patient a cholecystoduodenal 
fistula was present; for 17 patients there 
was no mention of the presence or absence 
of stones. Six patients had a second pri­
mary cancer: the uterus, kidney, rectum, 
breast, colon and ovary were affected.
Spread
Metastatic spread chiefly involved the he­
patobiliary region (Table VI). The regional 
nodes (i.e., cystic duct node, common duct
TABLE V.—Classification of Cancer by H isto­
logic D iagnosis
Histologic diagnosis
No. (and %) 
of patients 
(:n = 108)
Adenocarcinoma..........................
Epidermoid carcinoma................
Adenoacanthoma.........................
96 (89) 
7 (6.5) 
5 (4.5)
TABLE VI.—P rincipal Sites of M etastasis
No. (and %)
Site of patients
Regional nodes............................. 85 (79)
Liver.............................................  . 82 (76)
Contiguous only...................  29 (27)
Contiguous and distant.......  53 (49)
Distant only......................... 0 (0)
Lesser omentum..........................  43 (40)
Greater omentum........................  24 (22)
Gastroduodenal area...................  17 (16)
and superior pancreatic nodes) were in­
volved in 85 patients (79%). The liver was 
the next most frequent site of metastases, 
in 82 (76%). Distant spread alone to the 
liver did not occur in this series.
Survival
Of the 108 patients 7 (6.4%) were alive 
5 years after diagnosis (Fig. 1). The 5-year 
survival rate for curative resections was 
33% (7 of 21) (Fig. 2). The 1-year and 3- 
year survivals, after laparotomy only and 
after palliative resection, were identical: 5 
and 2% , though the survivals at 3 and 6
survival (%)
MONTHS
Fig. 1.—Primary carcinoma of gallbladder.
Survival for 108 patients related to operative man­
agement.
25
14
2
41
6
3
41
52
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months were slightly higher after palliative 
resection, which probably reflects the extent 
of the disease more than the type of opera­
tion. Evidence that the mean postoperative 
survival time is influenced by the extent of 
disease found at laparotomy is supported by 
the observation that it is 7 months when 
nodes only are involved, but 4 months in 
patients with liver metastases also. The 
mean survival time, without gross visible 
metastases at operation, was 3 years.
D iscussion
Gallbladder carcinoma is predominantly 
a disease of older women, found in approxi­
mately 1% of all gallbladder operations.-’ 19 
In our experience, it represents 0.6% of 
all cancers (exclusive of skin cancer).
The signs and symptoms are unspecific 
and simulate those of benign gallbladder 
disease.6- 16' 18- 20 Consequently, when ac­
companied by a history of weight loss, parti­
cularly in an older person, these should 
alert the physician to the possibility of can­
cer. In the present series the diagnosis was 
never made preoperatively in patients in 
whom curative resection was possible; con­
versely, when preoperative diagnosis was 
made or suspected, resection, even pallia­
tive, was rarely possible.
There are no specific routine laboratory 
or radiologic features. Barium meal not in­
frequently shows modifications in the antro- 
duodenal area;13' 19' 21- 22 however, these 
can be found in benign acute inflammatory 
gallbladder disease. A tortuous and irregular 
cystic artery, tumour staining and enlarge­
ment of the area supplied by the artery 
giving the champagne-glass appearance is to 
some degree specific of carcinoma of the 
gallbladder;21 but angiography cannot be 
advanced as a routine method of investiga­
tion, and its usefulness in early cases is 
probably minimal.
In our patients, except for one, operations 
that were thought to result in complete re­
section were accomplished before the sur­
geon was aware that carcinoma of the gall­
bladder was present. In other words, ap­
parently complete resection was accom­
plished by routine cholecystectomy, and this 
is certainly, from an oncologic point of 
view, a very limited cancer opera­
tion.r>- 14- 17- 19 Both surgeon and patient
were naturally reluctant to agree imme­
diately to a second operation. Immediate 
opening of all specimens by surgeon and 
pathologist, and frozen-section examination 
of any suspicious area, would eliminate un­
expected pathologic reports4 and permit at 
the same operation a more adequate resec­
tion.12 The seven 5-year survivors were 
among the 20 patients who underwent blind 
resection by simple cholecystecomy without 
the surgeon’s knowledge of the presence of 
cancer; a more adequate cancer operation 
in such patients might increase the survival 
rate.
In patients in whom the gallbladder was 
opened and carcinoma was discovered, 
stones were found in all except one. This 
association, noted by others619 in 60 to 
100% of patients, raises the problem of 
the carcinogenicity of gallstones. Prophylac­
tic removal of all stone-containing gallblad­
ders on this indication alone, however, ap­
pears difficult to support. Since 1000 such 
cholecystectomies would yield 10 cancers, 
and assuming an increased cure rate of 
50%, the patients thus “saved” would be 
offset by a surgical mortality of 0.5%, 
which is minimal in an unselected group of 
patients.7'9 We think a better reason to ad­
vocate cholecystectomy, apart from the re­
lief of symptoms, is the avoidance of much 
more frequent complications such as acute 
cholecystitis, choledocholithiasis and pan­
creatitis.1- 13'2:{
Our experience confirms the work of 
Fahim10 on metastatic routes of spread of 
gallbladder carcinoma. Lymphatic spread to 
the cystic duct node and along the common 
duct nodes to the retropancreatic nodes ap­
pears to happen first, together with direct 
invasion of the liver at the gallbladder 
fossa. Distant liver metastasis denotes pres­
ence of a long-standing cancer; this did not 
occur in the present series without spread 
by continuity. Fahim has reported a case of 
a cancer lying on the hepatic side of the 
gallbladder with a positive paracholedochal 
node without liver involvement at autop­
sy.11 Booher and Pack3 and Wolma and 
Lynch24 have also reported two similar 
cases. That direct involvement of the liver 
also happens early is evident from a report 
by Brasfield5 who, after performing a rou­
tine cholecystectomy, did a right hepatic
Ja n u a ry  1976 THE CANADIAN JOURNAL OF SURGERY 31
lobectomy and found microscopic foci of 
carcinoma in the gallbladder fossa, with 
negative nodes. Knowledge of these routes 
of spread is of prime importance in per­
formance of resection of gallbladder cancer 
that is more adequate than is afforded by a 
simple cholecystectomy. In this series, 21 
cholecystectomies were curative in intent; 
that is, no evident disease was left, yet 14 
patients died from cancer.
It is with this last group of patients that 
the greatest improvements are possible. An 
adequate operation in localized carcinoma 
of the gallbladder should include removal 
of known lymphatic routes of spread com­
bined with at least a wedge resection of the 
liver at the level of the gallbladder fossa. 
We believe such an operation is not beyond 
the tolerance of the older patients, in whom 
we unhesitatingly perform abdominoperineal 
resection of the rectum or radical gastrec­
tomy. In other patients with evident cancer 
in the gallbladder fossa, extensive hepatic 
resection can be performed by an exper­
ienced surgical team, at least in the younger 
patients, though, in this latter group, the 
possibility of increasing survival is probably 
less than in other patients. Gastroentero­
stomy may be considered in patients with 
locally advanced disease and minimal liver 
involvement.
Survival for the whole group was low, 
though a 5-year survival rate of 33% was 
obtained after “curative” resection.
Conclusion
Our experience with 108 primary gall­
bladder carcinomas shows that it represents 
less than 1% of all cancers (0.6%), and 
that 20% of cancers arise in the hepato­
biliary-pancreatic area. It is primarily a 
disease of older women. In early cases, there 
were no specific signs or symptoms, other 
than those of benign gallbladder disease.
Gallbladder carcinoma spreads first to 
regional nodes along the cystic and common 
ducts, and to the liver at the gallbladder 
fossa. Later spread is chiefly to the liver, 
lesser and greater omentum and gastro­
duodenal area.
For all patients the 5-year survival rate 
was 6.4% , though in 21 patients in whom 
resection was thought to be curative, the 
5-year survival rate was 33% . All these
resections except one were done without 
the surgeon’s knowledge of the presence of 
cancer. Hopes for improving survival rates 
lie in recognizing, at the time of operation, 
that one is dealing with a primary gallblad­
der carcinoma, so that an adequate cancer 
operation is performed; that is, wedge re­
section of the liver at the level of the gall­
bladder fossa combined with resection of 
regional lymph nodes.
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GLIMPSES OF SURGICAL HISTORY: G FOR GASTRIC SURGERY, 
GASTROSTOMY, BEAUMONT AND ST. MARTIN
D. A. E. SHEPHARD
The first gastric operations were necessi­
tated by the exigencies of trauma, and 
elective G ASTRIC SURGERY is of rela­
tively recent origin. The first planned 
G ASTRO STO M Y, for example, was per­
formed in 1602, by Matthis of Prague, and 
the second in 1635, by Swabe, an itinerant 
surgeon, who had passed a knife down the 
throat of this patient to induce vomiting —  
which caused the patient to swallow the 
knife instead. But the most celebrated gas­
trostomy, truly of traumatic origin, dates to 
1822: the surgeon was William Beaumont 
and the patient was Alexis St. Martin.
The Beaumont-St. Martin story does not 
require description here, but some of its 
lesser known aspects do bear repetition in 
view of the theme of this alphabetic look at 
the history of surgery: how persons other 
than surgeons have influenced the develop­
ment of surgical art. One such certainly was 
St. Martin, who, because he allowed Beau­
mont to study the actions and reactions of 
his stomach, appreciably advanced the un­
derstanding of surgical physiology.
Beaumont, remembered by Osier as “the 
pioneer physiologist of America”, was an 
accomplished surgeon besides, as his care of 
St. Martin proved. But two points must be 
made: St. Martin’s stomach wound was 
important to Beaumont because it repre­
sented the meeting of the man and his 
opportunity, and Beaumont was extraordi­
narily diligent in pursuing four series of 
studies of gastric digestion despite the diffi­
culties posed by his peripatetic military 
career, St. Martin’s occasional, but natural, 
desire to return to his native Canada from 
various parts of the United States (wherever
Beaumont happened to be), the lack of re­
search facilities, and the financial costs 
involved. Even so, Beaumont was remark­
ably successful in persuading both St. 
Martin to stay with him as his research sub­
ject and the US War Department to employ 
St. Martin so he could be at his side during 
his researches. Thus Beaumont was enabled 
to conduct 238 experiments on St. Martin 
over 11 years and to write his 1833 master­
piece, “Experiments and Observations on 
the Gastric luice and the Physiology of 
Digestion”.
St. Martin was, not surprisingly, very 
different from Beaumont, who was “a hum­
ble inquirer after truth —  a simple experi­
menter”. Beaumont treated him carefully 
for 2 years but St. Martin would not accede 
to Beaumont’s request to suture the lips of 
the gastrostomy wound together —  and so 
he unwittingly gave Beaumont the idea and 
opportunity for his great work. But St. 
Martin, a simple voyageur, periodically 
eluded Beaumont by returning to Canada. 
He knew Beaumont had made both of them 
famous and that he could demand money 
for his services —  and other scientists were 
interested in him too —  but he remained 
unreliable and truculent, perhaps unsurpris­
ingly. A s St. Martin himself wrote to Beau­
mont after disappointing him,
“This’s just a snatch of Monsieur’s ways,
Thus go’s he on in tricks and lies,
And thinks to get well paid for it.”
But patients are not machines, and sur­
geons must at times recall the debt that 
surgery owes to them, one of whom was 
Alexis St. Martin.
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DELAYED PRIMARY CLOSURE IN COLON OPERATIONS*
M. E. PAUL, MD, W. J. WALL, MD, FRCS[C] and J. H. DUFF, MD, FRCS[C]
Summary: Secondary closure of incisions by 
tape is a simple, safe procedure. In a retro­
spective series of 179 contaminated surgical 
wounds (incisions for colon operations) delayed 
wound closure resulted in a lower incidence of 
wound infection (5 .8% ) than did primary closure 
of similar wounds (11.8%). Although wounds left 
open do become infected, the acute swelling 
and systemic signs typical of an infection in a 
closed wound never develop. Delayed closure 
facilitated wound healing in hospital: only 3.8% 
of patients thus treated left hospital with open 
wounds, but 9.5% of patients whose wounds 
were closed primarily left hospital with wounds 
that were partially or completely open.
Resume: Une fermeture secondaire au moyen 
d'un ruban adhesif est une methode simple et 
sans danger. Apres avoir passe en revue une 
serie de 179 plaies operatoires contaminees (in­
cisions pour interventions sur le colon), la fer­
meture retardee de la plaie a permis de reduire 
la frequence de I'infection de la plaie (5.8%) si 
on compare ces resultats a ceux que donne la 
fermeture primaire (11.8%). S ’il est vrai que le 
fait de laisser les plaies ouvertes ouvre la voie 
a I'infection, il est tout aussi evident que la 
tumefaction aigue et les signes generaux qui 
sont typiques de I’infection d'une plaie suturee 
ne se manifestent jamais. La fermeture retardee 
a facilite la cicatrisation de la plaie durant le 
sejour a I'hopital: un petit nombre des operes 
de la sorte (3 .8% ) ont quitte I’hopital avec des 
plaies ouvertes, tandis que 9.5% des operes 
ayant eu une fermeture primaire ont quitte I’ho- 
pital avec des plaies qui etaient partiellement 
ou completement ouvertes.
W o u n d  infections cause appreciable mor­
bidity and economic loss. They develop in 
approximately 7.4% of the 18 million peo­
ple having operations yearly in the United 
States, with resultant cost of approximately 
9.4 million dollars, or $7000.00 per infec­
tion. 1 Many of these wound infections follow 
colon operations that must be considered 
contaminated. To decrease the incidence of 
wound infections both the use of antibiotics
*From the departments of surgery, University 
Hospital and Victoria Hospital, and the Univer­
sity of Western Ontario, London, Ont.
Reprint requests to: Dr. J. H. Duff, Department 
of surgery, University Hospital, 339 Windermere 
Rd., London, ON N6A 5A5.
and the technique of delayed closure have 
been suggested.
John Hunter2 in 1794 was among the 
first to describe the advantages of delayed 
wound closure. Military surgeons have long 
been convinced of the value of delayed 
closure for contaminated wounds; for exam­
ple, the NATO handbook, summarizing ex­
perience gained in the two world wars and 
in the Korean war, states that, after thorough 
debridement of injured tissues, “the second 
step is delayed primary wound closure, pre­
ferably three to seven days after injury, the 
indication for closure being the healthy ap­
pearance of the wound”.3 Before the use 
of tape,* delayed wound closure usually 
required a general anesthetic, as sutures 
were used after the wound edges were de- 
brided and freshened, and for this reason 
neither surgeon nor patient liked the pro­
cedure. In contrast, the use of tape permits 
secondary closure of wounds to be done 
with ease on the ward; and, cosmetically, 
wounds closed secondarily by tape are at 
least as good as those closed primarily by 
suture.
The aim of this study was to compare 
primary closure by suture with delayed 
closure by tape of contaminated wounds 
with regard to incidence of infection and 
wound status at the time of discharge from 
hospital.
M e t h o d s
A retrospective study was conducted of 
the records of all patients who underwent 
colon operations between November 1972 
and July 1974. For all colon operations that 
are classed as contaminated, we collected 
data relative to the condition requiring co­
lonic surgery, the type of bowel preparation, 
the incidence of wound infections, the 
status of the wound at the time of discharge 
from hospital and the severity of systemic 
manifestations. The criterion for the diag­
nosis of wound infection was the presence 
of pus.
*Steri-Strips, 3M Company, Minneapolis, MN, 
USA.
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TABLE I.—Types of Operations* TABLE II.—P athologic D iagnoses
Anterior resection.............................................. 60
Right hemicolectomy........................................ 34
Closure of colostomy........................................  33
Segmental resection..........................................  23
Total colectomy................................................. 17
Abdominoperineal resection............................. 10
Other...................................................................  2
Total............................................................  179
*Wounds referred to in this study were the ad- 
dominal incisions.
For wounds managed by delayed closure, 
the protocol was the following: At operation 
the fascia is closed and the skin and sub­
cutaneous tissue are held open with rayon 
and sterile gauze. The open wound is re­
dressed daily. When it is judged clinically 
suitable for closure—usually 3 to 5 days 
after operation— the wound is closed with 
tape on the ward. The dressing is removed 
and the skin surrounding the wound edge 
sprayed with an adhesive spray. The skin 
edges are approximated and held with rein­
forced Steri-Strips. In some patients, inter­
rupted skin edge sutures that have been 
placed and left untied at the time of opera­
tion are used to facilitate the application 
of the tape.
Results
Type of Operation and Colon Disease
There were 179 operations on the colon. 
Anterior resection was the most common 
operation (Table I) and cancer the most 
frequent diagnosis (Table II). There were 
more operations than diagnoses because of 
the number of colostomy closures. The ma­
jority of colon operations were elective 
(164) but among the 15 emergency opera­
tions the proportion of wounds managed by
Cancer of colon and rectum.............................. 92
Diverticulitis......................................................  28
Ulcerative colitis................................................ 11
Granulomatous colitis......................................
Ischemic colitis..................................................
Other................................................................... 16
Total.................................................... 155
delayed closure was relatively higher (7 of 
the 15) than among the elective operations 
(45 of the 164) (Table III).
Incidence of Wound Infections
The wound infection rate was distinctly 
lower in wounds closed secondarily than in 
those closed primarily (Table III); the over­
all incidence of 5.8% is similar to that often 
reported for clean or clean-contaminated 
wounds.4 With respect to the 164 elective 
operations the wound infection rate with 
delayed closure was lower still (4.4%); and, 
as expected, the overall incidence of infec­
tion was much higher for emergency opera­
tions.
Wound Healing
To be certain that delayed closure by 
tape did not adversely affect wound healing, 
we determined the state of the wound at 
discharge. For all colon operations, 12 
(9.5%) of wounds closed primarily were 
partially or completely open at the time of 
discharge from hospital whereas only 2 
(3.8%) of wounds closed secondarily were 
open at the time of discharge.
Antibiotic Therapy
Approximately one-third of patients in 
both main groups— primary and delayed 
closure—had no antibiotics as part of
TABLE III.—Wound Infection Related to Urgency of Operative Procedure and Method of
Wound Closure
Method of wound closure
Urgency of operation
Primary 
(n = 127)
Delayed
(n =  52) Total
Elective, no. of procedures..........................
Wound infection, no. (and % ) ....................
119
12(10.1)
45
2(4.4) 14(8.5)
164
Emergency, no. of procedures.....................
Wound infection, no. (and % ) ....................
8
3(38)
7
1(14) 4(27)
15
Elective +  emergency procedures.............
Wound infection, no. (and % ) ....................
127
15(11.8)
52
3(5.8) 18(10.1)
179
January 1976 THE CANADIAN JOURNAL OF SURGERY 35
bowel preparation or in the immediate post­
operative period. All other patients received 
antibiotics systemically or orally as a pro­
phylactic measure. Variations in the type of 
antibiotic and the timing of administration 
made reasonable analysis impossible. How­
ever, wound infections occurred with equal 
frequency in patients receiving and not re­
ceiving antibiotics, and the use of antibiotics 
was not different in the primary and delayed 
closure groups.
D iscussion
The concept of delayed primary closure 
of contaminated wounds is not new and 
evidence has been presented to explain the 
resistance of open wounds to infection. 
Billroth3 applied virulent organisms to 
dressings covering granulating wounds and 
found that infection did not develop—but 
the same experiment on fresh incised 
wounds caused infections to develop; fur­
thermore, if the granulating wound was 
closed over an infecting inoculum of bac­
teria, infection occurred. Edlich and collea­
gues6 created wounds on the backs of 
guinea pigs and found that when such 
wounds were contaminated with Staphylo­
coccus aureus, the optimum time of delayed 
primary closure, without development of 
wound infection, was on or after the 4th 
postoperative day.
The number of bacteria contaminating 
the wound was recognized to be clinically 
important by French surgeons as early as 
1917.7 For example, in World War I, war 
wounds more than 15 hours old were de- 
brided, cultured, flooded with Dakin’s solu­
tion and packed open with flavine gauze. 
The patient was then sent to the base hos­
pital together with his culture plate. If no 
streptococci had grown, and if there were 
less than five colonies of other bacteria per 
plate, the pack was removed and the wound 
managed by delayed closure; if there were 
more than five colonies on the plate, the 
wound was left open and allowed to heal 
by secondary intention. It is now known 
that, in terms of tissue content, the critical 
concentration of bacteria necessary to cause 
wound infection is 105/g ,8 and skin-graft 
survival is 94% if the concentration is 
103/g  or less, but lower than 20% if the 
count exceeds 103/g.
Robson and his colleagues9’ 10 reported a 
retrospective study of delayed wound closure 
with quantitative tissue cultures. They 
studied 40 wounds, of which 20 were left 
open for delayed primary closure and the 
other 20 were closed primarily but reopened 
to drain wound infections. Delayed primary 
closure was then carried out for the latter 
group. The time of delayed closure was 
determined according to clinical criteria 
alone, although bacterial counts were done 
at the time of delayed wound closure. Of 
30 wounds in which the tissue concentra­
tion of organisms was less than 103/g, 28 
healed without complication, but none of 
the 10 wounds closed when the tissue bac­
terial concentration was greater than 105/g  
healed without infection.
Delayed primary closure was frequently 
used during the Vietnam war, and for con­
taminated wounds, Heaton and colleagues11 
reported an infection rate with this technique 
of 2.6%. A similar rate was reported for 
civilian patients with perforated appendici­
tis: Grosfeld and Solit1 - found that delayed 
primary closure decreased the wound infec­
tion rate from 34% to 2.3% .
There is thus abundant evidence, from 
the experience of military surgeons in at 
least four major wars and from numerous 
civilian studies, both clinical and experi­
mental, that proves beyond reasonable 
doubt that delayed closure decreases the in­
cidence of infection in contaminated wounds.
Another factor is the use of antibiotics. 
Whether antibiotic therapy can be used as 
an alternative to delayed closure or as an 
ancillary supportive measure with delayed 
closure is not yet clear. Cruse and Foord13 
could not show a decrease in the infection 
rate of contaminated wounds from the 
topical use of ampicillin and bacitracin. On 
the other hand, Polk14 has shown in a 
prospective study a decrease in the infection 
rate of contaminated wounds with the sys­
temic use of cephaloridine. Stone and 
Hester13 have reported data suggesting 
that delayed closure and antibiotic therapy 
(local and systemic) are alternative methods 
of lowering the infection rate in contamin­
ated wounds of patients with perforated ap­
pendicitis and traumatic perforation of the 
intestine. In that study, the incidence of 
wound infection with primary closure was
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60% , with delayed closure 20% , and with 
antibiotics and primary closure 15% . -c
Whatever the role of antibiotics, there is ' 
little justification in ignoring the evidence v 
for the value of delayed closure of con­
taminated wounds. The results of this study •* 
further support the argument for delayed 
closure and emphasize the ease with which 
this can now be accomplished with the use 
of tape. It is possible that the lowest rate of 
infection in contaminated wounds will be -< 
achieved with both delayed closure and anti­
biotics.
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DELAYED PRIMARY CLOSURE OF THE SKIN AND SUBCUTANEOUS 
TISSUE IN ABDOMINAL SURGERY*
A. D. McLACHLIN, MD, MSc, DPhil(Oxon), MS(Tor), FRCS(Eng), FRCS[C], FACS and
W. WALL, MD, FRCS[C]
Summary: Infection-prone abdominal incisions 
in 143 patients were managed by delayed primary 
closure of the skin and subcutaneous tissue of 
the abdominal wall. The overall wound infection 
rate was 1.4% and the rate for 74 open, large 
bowel operations was 2.7%. These rates com­
pare favourably with a rate of 3.1% for clean 
inguinal hernia repairs done by the same surgical 
team over the same period. Delayed primary 
closure, carried out on the ward 3 days after 
operation, was simple, easy and did not prolong 
hospital stay. Its use is recommended in closing 
all abdominal wounds associated with a special 
risk of infection.
Resume: Chez 143 malades enclins a I'infection 
des incisions abdominales, nous avons procede 
a la cicatrisation de la peau et du tissu sous- 
cutane par premiere intention retardee de la pa- 
roi abdominale. Le taux global de plaies infec- 
tees a ete de 1.4% et, dans 74 operations ouver- 
tes du colon, de 2.7%. Ces taux se comparent 
favorablement avec le taux de 3.1% pour des 
herniorraphies de hernies inguinales faites par 
la meme equipe chirurgicale durant la meme 
periode. La cicatrisation par premiere intention 
retardee, pratiquee dans la salle 3 jours apres 
('operation a ete faite simplement, facilement 
et n’a pas prolonge la duree de (’hospitalisation. 
Nous conseillons cette methode dans tous les 
cas ou existe un risque special d'infection.
T h e  resistance of an open wound to infec­
tion was demonstrated by Billroth in 1864.1 
A wound with tissue loss in the back of a 
dog was left open to develop a granulating 
surface. Repeated applications of dressings 
soaked in liquid feces or pus did not make 
the wound appear infected and the dog re­
mained healthy and without fever. But when 
the contaminated dressings were sutured 
into the wound, the wound edges soon be­
came swollen, liquid feces entered the su­
ture opening and fever developed. This basic 
concept that an open wound is less likely 
to become infected than a wound that has 
been sutured primarily has often been re-
*From the department of surgery, University of 
Western Ontario, London, Ont.
Reprint requests to: Dr. A. D. McLachlin, De­
partment of surgery, University Hospital, 339 
Windermere Rd., London, ON N6G 2K3.
vived, particularly in time of war.2 4 We 
have used this principle in selected cases 
since 1945r’ and have developed a method 
of placing the skin sutures in position at 
the initial operation, leaving them untied 
until the time of delayed primary closure.
In 1972, the frequency of infection in the 
subcutaneous tissue of the abdominal wall 
following colon surgery led us to begin leav­
ing the abdominal skin and subcutaneous 
fat open in all patients undergoing large 
bowel operations. Success with the method 
then led to its use in other abdominal 
wounds that were at special risk from in­
fection.
P atients , O perations and M ethods
Operations
Delayed primary closure of skin and sub­
cutaneous tissue of the abdominal wound 
was used in 143 patients from 1972 to 1974 
inclusive (Table I); all procedures were per­
formed by a single surgical team using estab­
lished surgical techniques. The details of 
the 74 open, large bowel operations are 
summarized in Table II; mechanical cleans­
ing and prophylactic systemic antibiotics 
(ampicillin and penicillin) were used in this 
group.
Of the 11 gastric operations 9 were 
gastrectomies. Nine operations on the biliary 
tract included common duct exploration and 
another six were reconstructive procedures. 
Of the 12 hernias treated by delayed primary 
closure 6 were irreducible, with 5 strangula­
tions; the rest were large or recurrent inci-
TABLE I.—Wound Infection R ate in Infec­
tion-Prone Abdominal Incisions in Operations 
M anaged by D elayed P rimary Closure
Type of operation
No. of 
patients
No. of wound 
infections
Large bowel, open. .. 74 2
Biliary tract.............. 24 0
Hernia....................... 12 0
Stomach.................... 11 0
Small bowel............... 5 0
Other......................... 17 0
Total.................. 143 2*
‘Wound infection rate, 1.4%.
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TABLE II.—Wound Infection R ate in Inci­
sions for Open , Large Bowel Operations 
M anaged by Delayed Primary Closure
Type of operation
No. of 
patients
No. of wound 
infections
Closure of colostomy. 16 0
Right colectomy........ 11 0
Anterior resection. . . . 10 0
T ransabdominal 
polypectomy........... 8 0
Abdominoperineal 
resection.................. 7 0
Sigmoid colectomy. . . 7 1
Total colectomy......... 4 0
Left colectomy........... 3 0
Other............................ 8 1
T otal.................... 74 2*
* Wound infection rate, 2.7%.
sional hernias requiring extensive tissue dis­
section. The 17 other operations included 
appendectomy (3), drainage of pancreatic 
pseudocyst (2), drainage of liver abscess (2), 
enteroenterostomy (6), repair of liver in­
jury (2), and splenectomy (2).
To estimate the rate of clean wound in­
fection for comparison, wound infection 
rates for all inguinal herniorrhaphies man­
aged by immediate primary closure over the 
same period by the same surgical team were 
analyzed. There were 65 patients in this 
group.
In accordance with the criteria established 
by the National Research Council study,6 a 
wound was considered infected if there was 
a purulent discharge, whether or not organ­
isms could be cultured from the purulent 
material. The postoperative follow-up period 
in all patients was long enough to rule out 
late wound infections.
Surgical Technique
In the operating room after closure of 
the fascia with stainless steel wire sutures, 
4-0 cotton skin edge sutures are placed at 
2-cm intervals and left untied. A sheet of 
fine polyester nonadherent dressing placed 
to the depth of the wound holds the skin 
and subcutaneous tissue apart and a sterile 
occlusive dressing is applied (Fig. 1). The 
wound edges are not packed open but mere­
ly held apart by the nonadherent dressing 
until the 3rd postoperative day, when the 
dressing is removed on the ward using 
sterile technique and the wound closed 
(Fig. 2). Mild sedation with meperidine and 
diazepam relieves any discomfort.
Fig. 1.—Technique for delayed primary closure 
of abdominal wounds. Note single layer of fine 
polyester nonadherent dressing in depth of wound 
holding skin and subcutaneous tissues apart. 
Dressing is left undisturbed until time of delayed 
primary closure.
Skin sutures are removed on the 6th or 
7th day, and the adhesive strips are often 
removed at home by the patient about 10 
days after operation. No special precau­
tions in postoperative activity are necessary.
R e s u l t s
The wound infection rates relating to cus­
tomary closure of wounds and delayed pri-
4
on ward 3 days after operation. Gentle traction on 
tied sutures approximates skin edges accurately 
and makes application of tape easy; digital pres­
sure during application of tapes helps obliterate 
dead space.
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TABLE III.—Summary of Wound Infection R ates of Abdominal Incisions
Type of primary closure
No. of 
patients
No. of 
infections
Wound infection 
rate, %
Delayed
All operations............................................................. ..........  143 2 1.4
Colon operations only.............................................. ..........  74 2 2.7
Immediate (clean inguinal herniorrhaphy)................... ..........  65 2 3.1
mary closure are summarized in Table III. 
The two wound infections in the group of 
patients managed by delayed primary 
closure (overall incidence, 1.4%) both oc­
curred in patients undergoing large bowel 
surgery (incidence in large bowel operations, 
2.7%). One infection occurred 5 days after 
sigmoid colectomy; removal of two sutures 
and drainage were required. Culture grew 
Escherichia coli. The other infection was 
obvious when the dressing was removed in 
preparation for delayed primary closure. 
The patient, who was morbidly obese, had 
undergone transverse colectomy. The open 
wound drained a green purulent discharge, 
which yielded Pseudomonas organisms on 
culture and was left to close by secondary 
intention. In neither patient was the infec­
tion invasive and in both the wound healed 
satisfactorily.
Among the 65 patients undergoing in­
guinal herniorrhaphy during the same period 
there were two wound infections (clean 
wound infection rate, 3.1%). Both cases 
of infection occurred in patients who had 
undergone repair of recurrent hernia; puru­
lent discharge, noted at 7 and 10 days re­
spectively, yielded growth of Staphylococcus 
aureus on culture.
D iscussion
Various techniques of delayed primary 
closure have been described for the man­
agement of abdominal wounds in the pres­
ence of contamination.7'9 Irrigating solu­
tions and topical antibiotics have been used. 
The recommended interval between opera­
tion and delayed primary closure has been 
as long as 10 days. We have closed the 
wounds on the 3rd postoperative day and 
have found topical antibiotics and wound 
irrigation unnecessary. The amount of clot­
ted blood left in the wound when the initial 
dressing is removed is usually insignificant 
and is left undisturbed. Rarely, larger clots
have required removal before the wound is 
closed.
Closure of wounds on the ward has not 
distressed patients. Wounds in patients with 
a high risk of infection closed in this manner 
have manifested less local swelling and have 
seemed “quieter” than wounds closed with 
vertical mattress sutures or with buried su­
tures in the subcutaneous fat.
Delayed primary closure of wounds 
shortened the operating time and made less 
necessary the need for meticulous control 
of fine bleeding points compared with im­
mediate primary closure of the subcutaneous 
fat and skin. There was no delay in dis­
charge of patients from hospital and the final 
appearance of the incision was satisfactory.
The low wound infection rate of 2.7% 
obtained in open colon surgery by manag­
ing wounds in this manner is encouraging in 
view of the reported incidence of 8.9% to 
21.5% in clean-contaminated and conta­
minated cases, respectively.10
Co nclusion
Delayed primary closure of abdominal 
wounds is simple and easy for the surgeon 
and well tolerated by the patient. Infection 
rates for incisions of abdominal operations 
of 1.4% overall and 2.7% for large bowel 
procedures in comparison with a rate of 
3.1% for clean inguinal herniorrhaphies 
managed by immediate primary closure are 
encouraging. Hospital time is not prolonged 
and the appearance of the healed wound is 
good. General satisfaction and success with 
this method in colon surgery has led us to 
broaden its indications, and we are now 
using delayed primary closure in most ab­
dominal wounds that seem to have a special 
risk of infection.
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FOR RESIDENTS
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for the best paper on a surgical topic submitted by a surgical resident. To be given annu­
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SUBMUCOUS LIPOMA OF THE STOMACH: A CASE REPORT*
N. R. KALLIE, BSc, MB, ChB, DCP(Lond), DPath(Lond), FRCP[C1,
J. A. M. PETERS, MD, FRCS[C] and S. C. CHOW, MD, FRCP[C]
Summary: A 54-year-old woman presented with 
a 4-day history of melena and a 1-day history 
of hematemesis. Radiographs were suggestive 
of a malignant gastric polyp. Gastrotomy re­
vealed a polyp projecting from the anterior wall 
of the stomach. The polyp was excised and 
the patient has since been well. Although rare, 
gastric lipomas are important because they may 
cause hemorrhage, abdominal pain, dyspepsia 
and pyloric obstruction; moreover, they are 
amenable to surgical treatment.
Resume: line femme de 54 ans s'est presentee 
a I'hopital avec les symptomes suivants: melena 
depuis 4 jours et hematemese depuis 1 jour. 
Les radiographies laissaient supposer la pre­
sence d'un polype gastrique malin. line gastro- 
tomie a revele un polype faisant saillie en 
dehors de la paroi anterieure de I'estomac. 
Le polype ayant ete excise, la malade est, 
depuis, bien portante. Bien que rares, les lipo- 
mes gastriques ont une importance incontes­
table, parce qu'ils entrainent des hemorragies, 
une douleur abdominale, de la dyspepsie et une 
occlusion du pylore. Du reste, ils peuvent etre 
operes.
Since Virchow’s initial report of a gastric 
lipoma, found during an autopsy in 1863,1 
157 cases have been documented.2 Gastric 
lipomas are rare—benign tumours of the 
stomach constitute only 1% of all gastric 
neoplasms and of these 3% are gastric 
lipomas3—but they are important because 
of complications such as hemorrhage, abdo­
minal pain, dyspepsia and pyloric obstruc­
tion4 and because they are amenable to 
surgical treatment, in contrast to most 
malignant neoplasms of the stomach. We 
report a case of gastric lipoma with melena 
and hematemesis as the presenting features 
and in which surgical treatment was curative.
Case R eport
A 54-year-old woman was admitted to hos­
pital with a 4-day history of tarry stools, which 
had culminated in an episode of severe hema­
temesis on the day before admission; she be-
*From the Norfolk General Hospital, Simcoe, 
Ont.
Reprint requests to: Dr. N. R. Kallie, Pathologist, 
Norfolk General Hospital, Simcoe, ON N3Y 1T7.
came weak, dizzy and pale. Her past history 
contributed no relevant information.
The patient was pale and obese (103 kg). 
Her blood pressure was 130/90 mm Hg and 
her pulse rate was 96 beats/min; her admis­
sion temperature was 37.4°C and her respira­
tory rate was 20/min. Abdominal palpation 
revealed epigastric tenderness but no masses. 
Rectal examination disclosed only tarry stool 
on the examining finger. Other physical find­
ings were normal. Results of laboratory inves­
tigations were as follows: Hemoglobin concen­
tration, 10.3 g/dl; hematocrit, 30%; leukocyte 
count, 8.3 x 109/ / (80% polymorphonuclear 
cells); fasting blood glucose value, 129 mg/dl; 
blood urea nitrogen value, 39 mg/dl; serum 
electrolyte concentrations (mmol//), normal 
(sodium, 130; potassium, 4.4; and chloride, 
104); and urinalysis, normal. As a result of 
transfusion of 5 units of blood during the first 
3 days of treatment the hemoglobin concen­
tration increased to 12.2 g/dl.
Radiographic examination (Fig. 1) visualized 
a large irregular sessile mass projecting into 
the upper part of the lesser curvature of the 
barium-filled stomach. The tumour, which had 
a definite outline and was translucent, tended 
to move with a change in the position of the
F,g- 1-—Large irregular sessile mass projecting 
into upper part of lesser curvature of barium- 
filled stomach.
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Fig. 2.—Gastric polyp covered by cobble-stone mucosa. Arrow indicates one of four ulcers found. Note submucous fatty tumour exposed at sites of incisions.
patient. The pattern of the stomach was other­
wise normal and no abnormalities were noted 
in the esophagogastric junction and the duo­
denum.Continued gastric hemorrhage made laparo­
tomy necessary. Through an upper abdominal 
incision and a gastrotomy in the anterior wall 
of the stomach, a gastric polyp was seen 
projecting from the posterior wall midway be­
tween the cardia and the pylorus. The polyp 
( 8 x 6  cm) was excised at its base. There 
were no other abdominal visceral abnormal­
ities.Macroscopic examination (Fig. 2) revealed 
four benign ulcers on the surface of the polyp, 
the diameter of the largest being 2 cm. The 
ulcers were characteristically “punched out” 
with sharply defined margins. The edges were 
not raised. The mucosa of the remainder of 
the polyp had a cobble-stone appearance and 
was pink. A longitudinal section through the 
polyp disclosed a pale-yellow, soft, greasy, 
lobulated fatty tumour in the submucosal re­
gion (Fig. 3).Microscopic examination showed that the 
beds of the ulcers were covered by fibrinous 
exudates containing fragmented leukocytes, 
and the bases were fibrotic and contained 
lymphocytes, plasma cells and a few eosino­
phils. The muscular coat manifested general­
ized fibrosis. The submucosal region was re­
placed by adult adipose tissue, some areas 
containing foam cells and fibrous tissue tra- 
beculations containing small blood vessels 
were scattered throughout the tumour. A diag­
nosis of submucous lipoma of the stomach was 
made (Figs. 4 and 5). The mucosa of the
Fig. 3.—Longitudinal section through polyp re­vealing pale-yellow, soft, greasy, lobulated fatty tumour in submucosal region.
stomach away from the ulcer sites was normal.
The patient has been in good health since 
she was discharged from hospital on the 15th 
day.
D iscussion
Lipomas may arise in practically any body 
tissue. They are the second most common 
benign tumour of the gastrointestinal tract, 
myomas being more common. They evi­
dently develop in adults of both sexes6' 7 
and of all ages; Turkington4 reported an 
age range from 29 to 83 years. Weinberg and 
Feldman5 noted that they occur with greater 
frequency among diabetics.
Gastric lipomas have four outstanding 
clinical features— hemorrhage (which may 
be fatal), abdominal pain, dyspepsia and 
pyloric obstruction.4 Hemorrhage is the pre­
senting feature in about 50% of the re­
ported cases.4' 8-111 The characteristic radio- 
graphic features of the condition, well docu­
mented by Moore,11 are a circumscribed, 
punched-out filling defect, usually not on 
the curvatures; a relatively normal appear­
ance of the rugae; and lack of evidence for 
emptying of stomach and for spasm. The 
patient whose case we report presented with 
hematemesis and had a high fasting blood 
glucose (129 mg/dl) but the typical radio- 
graphic features were not clearly demon­
strated; the diagnosis of a malignant neo­
plasm was considered.
Over 60% of gastric lipomas are found 
in the antrum of the stomach.1- 4- 5> 12, 13 
Tumours located near the cardia cause dys­
phagia and those near the pylorus are liable 
to produce obstruction.1- 4 1 4  The incidence
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of ulcers associated with gastric lipomas is 
reportedly 33% .15 Usually the mucosa 
overlying the tumour is unremarkable; 95%  
of all gastric lipomas are submucous and 
the others are subserous;1- 3 12 the tumour 
itself is yellowish, soft, greasy and lobu- 
lated.4- 10 The histologic appearance is that 
of normal adipose tissue.
Malignant degeneration is not a feature 
of gastric lipomas,4' 1617 and liposarcomas 
of the stomach are almost unknown; how­
ever, when they do occur they are malig­
nant ab initio.
Various views have been put forward 
with regard to the origin of gastric lipoma.18 
Some believe that it arises from a fetal 
anlage separated during fetal life, and others 
believe that chronic irritation results in low- 
grade inflammation and hypertrophy with 
subsequent tumour formation. The latter 
view is not substantiated, because of the 
absence of inflammation and of metaplasia 
in most cases.
We thank Miss Cindy Maxwell for typing the 
manuscript, Mr. B. Cook and Dr. K. Shier for 
preparing the illustrations, Mrs. M. Carpenter 
for collecting the references and Dr. S. Moore 
for valuable criticism.
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ACUTE PERFORATION OF THE COLON*
A. A. LOZON, MD, FRCS[C] and J. H. DUFF, MD, FRCS[C]
Summary: Acute perforation of the colon causes 
fecal peritonitis, which is associated with high 
rates of morbidity and mortality. Findings in 
78 patients with perforation of the colon showed 
that the commonest causative condition was 
diverticulitis fin 42%) and that the commonest 
site was the sigmoid colon (in 65%). The over­
all mortality in this series was 49%, most of 
the deaths being due to peritonitis; the extent 
of anatomic spread of peritonitis was a major 
factor. The form of treatment was also a factor 
in mortality: mortality was lowest in patients 
treated by diversionary colostomy (only 38%) 
and highest in those treated by exteriorization 
of perforation (71%) and in those not treated 
operatively (71%). With respect to postoperative 
complications in patients who underwent oper­
ation, wound infection and pulmonary abnormal­
ities each occurred in 50%. This review suggests 
that current methods of management of patients 
with perforation of the colon are less than 
satisfactory.
Resume: La perforation aigue du colon cause une 
peritonite fecale laquelle s'accompagne d'une 
proportion considerable de morbidity et de mor­
tality. Apres avoir passe en revue les dossiers de 
78 malades ayant presente une perforation du 
colon, nous avons decouvert que I'etiologie la 
plus courante etait la diverticulite (soit chez 
42% des cas) et que le siege principal etait 
le colon sigmoide (dans 65%). Dans cette serie 
de patients le taux total de mortality etait de 
49%, la plupart des deeds etant attribuable a 
la peritonite; le degre de la propagation anato- 
mique de la peritonite representait un facteur 
capital de gravite. La forme du traitement a 
egalement joue un role dans la mortality, qui 
etait minimale chez les patients traites uni- 
quement a moyen d’une colostomie de deriva­
tion (38%), et maximale chez ceux qui avaient 
subi une exteriorisation de la perforation (71%) 
ainsi que chez les patients non operes (71%). 
En ce qui concerne les complications postope- 
ratoires, I infection de la plaie est apparue chez 
50% des cas et des anomalies pulmonaires sont 
apparues egalement chez 50% des cas.
*From the department of surgery, Victoria Hos­
pital, and University of Western Ontario, London 
Ont.
Reprint requests to: Dr. J. H. Duff, Department 
of surgery, University Hospital, 339 Windermere 
Rd„ London, ON N6A 5A5.
Perforation  is a life-threatening complica­
tion of most diseases of the colon and 
occurs in patients of all ages. Acute perfo­
ration causes fecal peritonitis, which may be 
localized or diffuse. Despite aggressive sur­
gical and medical management, fecal peri­
tonitis is associated with high rates of mor­
bidity and mortality. The aim of this study 
was to ascertain the incidence and sequelae 
of perforation of the colon and to deter­
mine whether morbidity and mortality could 
be related to various methods of surgical 
management.
M ethod
The charts of all patients with perfora­
tion of the colon treated from 1963 through 
1972 were reviewed retrospectively. During 
the same period the total number of pa­
tients admitted with injury or disease of the 
colon was determined. All cases of perfo­
rated colon were included if the diagnosis 
was confirmed by operation or autopsy.
R esults
Incidence, Age and Extent of Peritonitis
Of 1020 patients admitted to hospital 
with a disorder of the colon 78 (7.6%) had 
sustained a perforation. There were 41 men 
and 37 women; the average age was 54.9 
years, most being between 40 and 79 years 
old. For these 78 patients findings at oper­
ation or autopsy showed that 30 had a 
perforation with localized peritonitis and 
that 48 had perforation with diffuse peri­
tonitis.
Clinical Features
Fever was noted in 96% of patients. 
Radiographs (plain films and barium enema) 
were obtained in 61 (78.2%) of the pa­
tients; free air was visualized in 30% of 
these patients and barium enema was diag­
nostic of perforation in 34%. Although 
barium enema was contraindicated when 
the diagnosis of perforation of the colon 
was obvious, it was useful and extremely 
accurate when the diagnosis was in doubt.
In 21 of 25 patients barium enema was diag-
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nostic of perforation. Overall, radiographs 
provided a definitive diagnosis or were help­
ful in 36% of patients. Only 15 patients 
(19%) underwent sigmoidoscopy and in only 
5 was it helpful in determining the type of 
colorectal disease causing perforation.
Cause and Site of Perforation
The commonest cause of perforation of 
the colon was diverticulitis; this was the 
causative factor in 42% of patients. Ische­
mic colitis was the cause in 14%, trauma 
in 13%, perforating carcinoma in 9% , 
obstruction in 8% and radiation necrosis 
in 4% . Less common causes were ulcera­
tive colitis (2 patients), volvulus (2), gastro­
colic fistula (1) and stercoral ulceration (1). 
Together the latter conditions accounted for 
7.6% of perforations. Of the 11 patients 
with ischemic colitis, 4 had nonocclusive 
ischemia,1 3 had atherosclerotic vascular 
occlusion, 3 had undergone aortic resection 
before the perforation developed, 1 had 
sustained traumatic interruption of the vas­
cular supply as a result of a motor vehicle 
accident. As Fig. 1 shows, perforation oc­
curred most frequently in the sigmoid colon. 
In two patients sigmoidoscopy was the cause 
of the perforation.
TABLE I.—Organisms Cultured in 52 Patients
Proportion (%)
of patients
Organism with organism
Escherichia coli....................... 69
Clostridia sp,........................... 19
Anaerobic streptococci.........  19
Pseudomonas sp...................... 15
Bacteroides sp.*......................  12
Klebsiella sp............................  12
Proteus sp................................ 10
*For 1969 onwards.
Bacteriologic Findings and Antibiotic
Therapy
Bacterial cultures were obtained in 52 
patients; Escherichia coli was the organism 
cultured most frequently (Table I). Anti­
biotics were given to all but five patients. 
Ampicillin, chloramphenicol and gentamicin 
were the most commonly used, though since 
1969 chloramphenicol has been given infre­
quently and gentamicin more frequently.
Mortality
Overall, there were 3 8 deaths in the series 
(mortality, 49% ); 34 deaths were due to 
peritonitis (which included septic shock and 
impaired nutrition), 2 were due to pulmon­
ary embolism and 2 due to associated in­
juries from trauma (Table II).
TABLE II.—Cause of D eath in 38 Patients
Cause of death No. of patients
Peritonitis............................... 34
Pulmonary embolism............ 2
Associated injury.................. 2
Total............................... 38
Of the 78 patients, 71 underwent an 
operative procedure and 33 of them died. 
The mean duration between operation and 
death was 11 days. Seven patients did not 
undergo operation, and, five of these pa­
tients died. In two patients perforation 
was caused by a diagnostic barium enema 
and in one perforation was due to radiation 
necrosis. The only survivors of the group 
who did not undergo operation were the 
two patients in whom perforation developed 
during a barium enema.
Site of perforation and mortality.—  
Among the 51 patients in whom the sigmoid 
colon was perforated, 19 (38%) died, and 
among the 19 patients with perforations of
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TABLE III.—M ortality of Colon Perforation
Causative condition
No. of 
patients
No. of 
deaths
Mortality,
%
Diverticulitis............ 33 8 24
Ischemic colitis........ 11 10 91
Trauma..................... 10 7 70
Carcinoma................
Obstruction with
7 4 57
perforated cecum. 6 2 33
Radiation necrosis. . 3 3 100
Others....................... 8 4 50
Total................. 78 38 49
the cecum and ascending colon 12 (63%) 
died.
Cause of perforation, peritonitis and mor­
tality.— Details of mortality in relation to 
the cause of perforation are summarized in 
Table III. The extent of anatomic spread 
of peritonitis was a major factor in mortal­
ity. In the group of 30 patients who had 
perforation with localized infection or 
abscess formation, 7 (23%) died, but of 
48 patients with diffuse peritonitis, 31 
(65%) died.
Treatment and mortality.—Details of 
mortality in relation to operative manage­
ment of patients with perforation of the 
colon, particularly with regard to resection 
of the septic focus (perforation) and per­
formance of a diversionary procedure are 
presented in Table IV. Mortality was low­
est in patients in whom only a diversionary 
colostomy was performed; most of these 
patients had diverticulitis.
Since the primary pathologic lesion dif­
fered among treatment groups, a statistical 
comparison of mortality rates for different 
methods of surgical treatment is not valid. 
None the less, it is evident that for all meth­
ods of surgical management, the mortality 
was unacceptably high. Mortality of patients
TABLE IV.—M ortality of Colon Perforation
No. of No. of Mortality,
Treatment patients deaths %
Diversionary colos-
tomy only............
Resection of
34 12 35
perforation...........
Exteriorization of
24 12 50
perforation........... 7 5 71
Drainage only.......... 6 4 67
No operation............ 7 5 71
Total................. 78 38 49
TABLE V.—P ostoperative Complications of 
Colon Perforation
Complication No. (and %)
Wound infection................................  36 (50)
Localized peritonitis and abscess 11
Diffuse fecal peritonitis...............  25
Lung lesion......................................... 35 (49)
Septicemia..........................................  12 (17)
Wound dehiscence............................  4 (6)
Small bowel fistula..........................  2 (3)
treated by resection and diversion was sur­
prisingly high (50%).
Postoperative Complications
The complications of perforation of the 
colon are listed in Table V. Wound infec­
tions and lung lesions were found in half 
of the patients and septicemia occurred in 
nearly one-fifth. Radiologic diagnoses of the 
lung lesion included pneumonia, pulmonary 
congestion, pleural effusion and atelectasis. 
Though likely to have been present, shock 
lung was not diagnosed during the time of 
this review.
D iscussion
This study has shown that a wide variety 
of diseases of the colon are severe enough 
to require admission of patients to hospital. 
Perforation is the most grave complication 
of all of these diseases. The incidence in 
this study of perforation of hospital admis­
sions for colon diseases (7.6%) was sur­
prisingly high. But Watkins and Oliver2 
reported an incidence of 14% among pa­
tients entering hospital with diverticulitis, 
and Goligher2 reported an incidence of per­
foration among patients with ulcerative 
colitis ranging from 5 to 9% depending on 
the severity of the first attack. In toxic 
megacolon few patients survived perforation 
regardless of treatment, but when operation 
is performed before perforation occurs, mor­
tality approaches that of elective colon re­
section.2 In the patients whose cases were 
reviewed in this study, perforation was 
obviously a turning point in their disease 
from which only 50% survived. Diverticu­
litis and obstruction were the only condi­
tions in which the mortality of perforation 
was less than 50%.
The surgical approaches to perforation 
of the colon include peritoneal lavage, 
exteriorization of the perforated segment,
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*
C
4
*
January 1976 THE CANADIAN JOURNAL OF SURGERY 51
defunctioning proximal colostomy and, more 
recently, resection of the perforated segment 
with end-to-end anastomosis. The latter ap­
proach has merit because it permits removal 
of the source of peritoneal contamination, 
which may continue to leak fecal material 
despite proximal defunctioning. Madden and 
Tan4 reported an improved survival in pa­
tients with diverticulitis if the involved area 
was resected. In contrast, the findings of 
our study fail to support this approach: 
defunctioning colostomy alone was associ­
ated with the lowest mortality rate. Although 
the retrospective nature of the study and 
the varied causes of perforation make stat­
istical comparison invalid, it is clear that 
resection or exteriorization of the perfora­
tion was associated with an unacceptably 
high mortality, for 17 of 31 died.
Wound infection was the most frequent 
complication of perforation of the colon, 
occurring in over half the patients who had 
diffuse peritonitis. This finding strongly sug­
gests that skin closure should be abandoned 
in such patients in favour of secondary clos­
ure when the open wound is granulating 
and clean. In a recent review of wound 
infection in elective and emergency colon 
surgery, we found that 10% of wounds 
closed primarily became infected in contrast 
to only 4% in wounds packed open and 
closed secondarily by tape (unpublished 
data).
Our bacteriologic findings are very sim­
ilar to those of Storer.'1 Before 1969, anae­
robic cultures were not carried out routinely, 
thus all Bacteroides infections were diag­
nosed since 1969. Therefore, the true inci­
dence of Bacteroides infection is likely 
higher, as suggested by Beazley, Polakavetz 
and Miller.0
The incidence of lung complication was 
high (49%) but this finding supports work 
emphasizing the prevalence of lung lesions
in septic conditions.7 Though impossible to 
say in retrospect, present experience with 
peritoneal sepsis suggests that many of the 
pulmonary lesions observed would fulfil the 
criteria for the lung lesion of sepsis. This 
pulmonary complication is refractory to cur­
rent methods of treatment and often a direct 
cause of death in such patients.
C onclusion
This review suggests that the currently 
accepted methods of management for per­
foration of the colon are less than satisfac­
tory. At best, surgical treatment is only 
slightly better than conservative treatment. 
Moreover, mortality associated with various 
methods of surgical management is high. 
Thus, while anatomical cure is possible and 
usually accomplished without great diffi­
culty, the patient fails to survive because 
of the general effects of sepsis, one of which 
is pulmonary edema. Because prevention of 
colon perforation is frequently not possible, 
new approaches to this complication will be 
required to improve survival.
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DEXON: AN EXCELLENT SUTURE FOR MIDLINE INCISIONS*
D. M. GRACE, MD, FRCS[C]
Summary: In a period of 18 months, 100 midline 
incisions of 93 patients were closed with inter­
rupted 0 Dexon sutures. The Smead-Jones far- 
and-near stitch was used. There were no early 
disruptions and no incisional hernias in follow­
up periods ranging from 5 days to 14 months. 
Four wound infections healed readily without 
prolonged drainage. Incisional pain was minimal 
in all patients. A group of 18 patients with po­
tential for poor healing because of hemorrhage, 
sepsis, malignancy and steroids had no wound 
complications apart from an acceptable rate of 
infection. It is concluded that interrupted 0 
Dexon with wide fascial placement provides an 
excellent closure for midline incisions.
Resume: Sur une periode de 18 mois, nous avons 
ferine 100 incisions medianes chez 93 patients, 
au moyen de sutures interrompues de Dexon 0. 
Nous avons, a cet effet, utilise le point de 
Smead-Jones. Sur une periode de post-observa­
tion variant de 5 jours a 14 mois, nous n'avons 
constate ni rupture precoce ni hernie incisionel- 
le. Quatre cas de plaies infectees ont gueri 
rapidement sans long drainage. La douleur, au 
niveau de I'incision a ete minimale chez tous 
nos patients. Un groupe de 18 malades, dont le 
pronostic de guerison etait mediocre, en raison 
d’hemorragie, d'infection, de tumeurs malignes 
et d'emploi de corticoides n’ont eu aucune com­
plication sauf un certain degre, tres acceptable, 
d'infection. Nous croyons done pouvoir conclure 
que la suture interrompue avec le Dexon 0, 
constitue un excellent moyen de fermer les in­
cisions medianes.
A variety of sutures and incisions may be 
used with good results in abdominal opera­
tions, but no one method is perfect. Trans­
verse incisions are useful and comfortable, 
especially for obese patients, but operating 
time and blood loss may be greater than 
with vertical incisions. Midline incisions 
offer the benefits of rapid entry, minimal 
blood loss and extensibility. With respect to 
sutures, stainless steel wire provides secure 
closure of midline incisions but can cut 
through fascia, and there is greater wound
’ From the department of surgery, University Hos­
pital and University of Western Ontario, London, 
Ont.
Reprint requests to: Dr. D. M. Grace, Depart­
ment of surgery, University Hospital, 339 Winder- 
mere Rd., London, ON N6A 5A5.
discomfort, especially in thin active people; 
nonabsorbable sutures such as silk handle 
well and give initial security but may lead 
to wound sinuses and late hernias if infec­
tion occurs; and chromic catgut shows great 
variation in absorption, especially in the 
presence of infection, and is not reliable 
enough for secure closure of midline inci­
sions.
Initial experience with polyglycolic acid 
(Dexon) suggested that it might offer no 
advantages over chromic catgut1- 2 but sub­
sequent experience has shown that Dexon is 
satisfactory for abdominal incisions.3- 4 It 
has been used for a variety of incisions and 
we have found it to be satisfactory for ver­
tical or transverse abdominal incisions. 
There is a clinical suspicion that vertical 
incisions do not heal as well as transverse, 
and many surgeons are reluctant to use ab­
sorbable sutures for midline incisions. In 
this paper we report our initial experience 
with Dexon in the closure of 100 midline in­
cisions in operations on 93 patients. We also 
report results of a more detailed study in 
18 poor-risk patients in this group to demon­
strate both wound security and comfort.
Patients and M ethods
A total of 100 midline incisions in 93 
patients (age range, 6 to 85 years) were 
closed with Dexon between the first use of 
this method in December 1973 and May 
1975 (Table 1). Five patients had two oper­
ations through the same midline incision 
with closure by Dexon and one had three
TABLE I.—Types of Operations in which 
M idline Incisions were Closed with Dexon 
Sutures
Type of operation No. of operations
Biliary tra c t......................... 33
Large bowel......................... 16
Stomach................................ 15
Laparotomy......................... 13
Splenectomy........................
Hiatus hernia......................
9
3
Small bowel......................... 3
Abscess drainage................. 2
Pancreas............................... 1
Miscellaneous...................... 5
Total........ 100*
’These 100 operations were performed on 93 patients.
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TABLE II.—Poor-R isk P atients with Incisions Closed by D exon
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Patient
no.
Age
(yr) Procedure
i 30 Splenectomy
2 27 Colectomy, proctectomy, 
ileostomy
3 21 Drainage of pancreatic 
abscess
4 70 Hartmann procedure
5 25 Vagotomy, pyloroplasty, 
oversewing bleeding 
duodenal ulcer
6 74 R. colectomy
7 57 Splenectomy
8 32 Appendectomy
9 48 Subtotal colectomy
10 75 Hartmann procedure
11 49 Exploration of common 
bile duct
12 63 Small bowel resection
13 57 Vagotomy, pyloroplasty, 
oversewing bleeding 
duodenal ulcer
14 20 Laparotomy
15 73 R. colectomy
16 41 Closure of perforated 
duodenal ulcer
17 64 Repair of bile duct 
stricture
18 25 Closure of perforated 
gastic ulcer
*DPC — delayed primary closure.
Wound
Comment complications
Idiopathic thrombo­
cytopenic purpura, 
on steroids 
Ulcerative colitis, 
on steroids
Large lesser sac abscess 
grew Staphylococcus 
sp. and Clostridium sp. 
Perforated diverticulitis, 
peritonitis; on steroids 
for asthma
Renal transplant; steroids 
and azathioprine; 
hemoglobin, 2.7 mg/dl, 
albumin, 1.4 g/dl 
Cecal volvulus, diabetic 
Obese, cirrhotic, 
hypersplenism 
Perforated appendix, 
peritonitis, septic 
shock
Brain tumour (on ster­
oids), splenic flexure 
carcinoma, gangrenous 
cecum
Perforated diverticulitis, 
rheumatoid arthritis; on 
steroids
Carcinoma of common 
duct; postop. radio­
therapy
Perforated Meckel’s 
diverticulum; old TB, 
thoracoplasty; respi­
rator for 4 d 
Hemoglobin, 2.9 g/dl; 
severe multiple 
sclerosis 
TB peritonitis 
Large bowel obstruction, 
gangrenous cecum 
Massive peritonitis, re­
current brain tumour; 
on steroids 
Cholangitis, hepatic 
duct stricture 
Ulcer perforated 48 h, 
ulcerative colitis; on 
steroids
None
None
None (DPC)* 
None (DPC) 
None
None (DPC) 
None
Infection, 
cleared well
None (DPC)
None (DPC) 
None
None (DPC)
None (DPC) 
None
None (DPC) 
None (DPC)
None (DPC)
Infection, 
healed well
Follow-up
period
1 yr
14 mo 
10 mo
3 mo
1 yr
6 mo 
10 mo
13 mo 
3 mo
5 d 
(died)
10 mo 
(died)
3 mo
6 mo
3 mo 
6 mo
7 d 
(died) 
3 mo
2 mo
operations. During the initial 6 months of 
the study, incisions in a number of poor- 
risk patients were closed with stainless steel 
wire, but as confidence in Dexon increased 
it was used more often until all midline in­
cisions from May 1974 through May 1975 
were closed with this suture. Particular at­
tention to wound healing was paid in a 
subgroup of 18 poor-risk patients (Table 
II). Subcostal incisions for cholecystectomy 
were used frequently during the initial 
months of the study and were closed suc­
cessfully with Dexon, but these cases have
been excluded. Later, most cholecystec­
tomies were performed through midline in­
cisions, and were closed with Dexon. 
Data for all midline incisions, whether new 
or through an old incision, have been in­
cluded, except for those for midline inci­
sional hernias closed with stainless steel 
wire.
The method of closure was a modification 
of the stainless steel wire technique used 
successfully at this centre by Dr. A. D. 
McLachlin for many years. The peritoneum 
is first closed with continuous 2-0 chromic
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Fig. 1.—Method of closure of midline incision 
with Smead-Jones far-and-near stitch. Peritoneum 
in lower incision is usually not closed as separate 
layer.
catgut. Interrupted 0 Dexon is then used 
for closure of the fascia. Sutures (length, 
46 cm) are double-threaded on a large atrau­
matic disposable needle and placed 1 to
Fig. 2.—Cross-section of abdominal wall show­
ing placement of far-and-near stitch. Wide su­
ture often passes through rectus muscle.
1.5 cm apart. The Smead-Jones5 type of 
far-and-near technique is used (Figs. 1 and 
2): the initial wide bite of the fascia is at 
least 2 cm from the edge for secure holding 
power and the second bite takes about 0.5 
cm of fascia, the initial placement in each 
case being on the side away from the oper­
ator. Each stitch is held up with a Kocher 
clamp to facilitate placement of the next 
and to prevent penetration of underlying 
peritoneum. All sutures are placed before 
they are tied; to prevent slipping, a two- 
handed tie is used and a double throw is 
used first followed by three square knots. 
The skin is closed by means of any usual 
technique, though we have lately used de­
layed primary closure for incisions in many 
contaminated or dirty cases. In these cases 
the subcutaneous tissues are lined with 
rayon and the wounds taped closed at 5 days 
or when clean.
R esults
As have others,6 we found Dexon to be 
stronger than chromic catgut of the same 
calibre. Because Dexon is relatively inelastic 
and braided it tends to cut through soft tis­
sues and is not suitable for closure of the 
peritoneum; we found, however, that it did 
not show this tendency after wide placement 
in fascia. Handling was good and its knot­
ting characteristics, though not as good as 
those of silk, were considerably better than 
polypropylene. Dexon knots did have some 
tendency to slip, but the two-hand tech­
nique with an initial double throw prevented 
this problem.
There were no early instances of wound 
disruption and no incisional hernias devel­
oped during an average follow-up period of 
6 months (range, 5 days [in a patient who 
died from peritonitis] to 14 months). We 
were initially concerned about the holding 
power of Dexon in all patients, especially 
those with sepsis, bleeding or malignant 
neoplasms and those taking steroids. The 
clinical details of a group of 18 patients in 
whom impairment of healing might have 
been expected are summarized in Table II. 
There were no early wound disruptions or 
late hernias in this group. Two wound in­
fections cleared readily with appropriate 
treatment.
r
4
r
r * -
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TABLE III.—Classification of Wounds and 
Infections
Classification*
No. of 
incisions
No. (and %) 
of infections
Clean........................... 55 1 (1.8)
Clean-contaminated.. 18 1 (5.6)
Contaminated............ 17 o ( 0 )
Dirty........................... 10 2 (20)
Total.......... 100 4 ( 4 )
♦Criteria of National Research Council study.7
The incidence of wound infection is sum­
marized in Table HIT The infection in the 
one clean case was localized to the lower 
incision and appeared 3 weeks after opera­
tion. All infections cleared readily with 
local treatment and none were followed by 
prolonged drainage or incisional hernias. 
The infections that complicated healing of 
2 of the 10 dirty wounds occurred in wounds 
that were closed primarily; we would now 
use delayed primary closure for such inci­
sions. Of the 27 wounds that were con­
taminated or dirty 17 were treated by de­
layed primary closure. This technique did 
not seem to affect the healing of incisions 
closed with Dexon, and prolonged drainage 
did not occur.
Of the 93 patients in this series, 6 pa­
tients died, from 5 days to 8 months after 
operation. Some patients from out of town 
were lost to follow-up, but 73% of surviv­
ing patients were seen or contacted by tele­
phone within 1 month of writing and all 
surviving patients have been followed up 
for at least 1 month. Although our study 
was not a controlled one, our impression is 
that Dexon gives much less long-term wound 
discomfort than wire.
D iscussion
In spite of early pessimistic reports, Dexon 
has proven successful for abdominal inci­
sions.3’ 4 It loses strength more slowly 
than catgut in experimental animalss and in 
humans9 and loses less strength than catgut 
on wetting and knotting.6 As others6 have 
found, Dexon appeared to be stronger than 
chromic catgut of the same calibre. Our 
studies show that Dexon is excellent for 
midline incisions, even in poor-risk patients. 
The closure is secure even in the presence 
of infection. We can make no claims for 
prolonged security but no incisional hernias
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have developed up to 14 months after opera­
tion.
The far-and-near (Smead-Jones) stitch 
is superior to other methods of suturing, ■’ 
and external retention sutures are unneces­
sary; however, wide placement of the su­
tures in the fascia is important to give ade­
quate holding power. We found healing ade­
quate aftei; reclosure of old midline incisions 
but the development of an incisional hernia 
after closure of an old paramedian incision 
with Dexon would make one more cautious. 
It is likely that one could use continuous 
Dexon for fascial closure, as we have done 
successfully in a large number of dogs, 
monkeys, baboons and pigs; but, although 
some objections may be theoretical, we still 
have reservations about such a closure. A 
continuous suture technique is not as strong 
as that using interrupted simple sutures,5 
and neither technique is as strong as the far- 
and-near technique we use.
The rate of wound infection in this study 
was acceptable by current standards.10 The 
clean wound infection rate of 1.8% is the 
best judge of technique and our only case 
of infection was late and localized. The rate 
of infection in dirty wounds could have 
been reduced even further by using delayed 
primary closure in all such cases. This tech­
nique is now standard for contaminated and 
dirty cases in our centre and does not seem 
to affect the holding power of Dexon. 
Whether Dexon contributed to the low in­
fection rate is not clear. Certainly this suture 
produces little tissue reaction8 and less in­
fection in contaminated tissue than catgut,11 
also, Dexon does not lead to sinus forma­
tion if wound infection does occur.
The advantages of Dexon over other su­
tures for abdominal incisions are readily 
stated. It offers more sustained holding 
power and reliable absorption than chromic 
catgut, with less tissue inflammation and 
probably a lower contribution to infection. 
Dexon seems to retain strength in the pres­
ence of infection better than catgut, but it 
does tend to cut through soft tissues more 
than catgut. Dexon does not offer the sus­
tained holding power of wire, though wire 
sutures do break eventually, but it is easier 
to handle and has less tendency to cut 
through fascia. The incidence of incisional
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hernias with each is low, but Dexon seems 
to give a more comfortable wound than 
wire. A minor advantage of Dexon is the 
ease of re-entry should a second operation 
be necessary. Silk is slightly easier to han­
dle than Dexon, but causes wound sinuses 
and often late hernias if infection occurs. 
Most other nonabsorbable braided sutures 
have the same properties. Polypropylene 
is an inert monofilament suture with sus­
tained holding power that is satisfactory for 
midline incisions, but it is difficult to handle, 
requires multiple knots and may cause 
wound sinuses, though much less often than 
silk.12 Other absorbable sutures such as 
polyglactin1'5 are being developed and these 
may be satisfactory for abdominal closure 
in the future. However, it would seem dif­
ficult to improve on the midline incision 
and Dexon closure that have given wound 
security and comfort. The complete absence 
of dehiscence, evisceration and incisional 
hernia is proof of the effectiveness of the 
suture.
In the present series, therefore, there were 
no failures of technique associated with the 
use of Dexon. In fact, we have noted only 
one failure since we started using Dexon. 
This occurred in a patient not included in this 
study because she had a paramedian inci­
sion. The initial incision was made else­
where in a patient with perforation of the 
cecum associated with a large bowel ob­
struction caused by a carcinoma of the 
splenic flexure. After a prolonged illness 
resulting from sepsis, shock lung and renal 
failure, left colectomy was carried out at our 
centre. The patient was being treated by 
hemodialysis at this time (serum creatinine 
concentration, 12 mg/dl). Fascia and muscle 
were closed in one layer with Dexon sutures. 
There were no early wound complications, 
but, 4 months later, an incisional hernia 
was noted. It was not clear whether the
hernia resulted from suture failure, poor 
wound healing in a debilitated patient with 
renal failure or inadequate bites of a pre­
viously sutured paramedian incision. Eight 
old midline incisions were closed from 1 
week to 3 years after the initial procedure 
without complication.
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SURVIVAL IN BREAST CANCER: STUDY OF 283 PATIENTS*
LUC DESCHENES, MD, FRCS[C] and JACQUELINE FABIA, MD, SD(Hyg)
Summary: Records of 283 women with breast 
cancer diagnosed from 1965 through 1973 at 
I’Hopital du Saint-Sacrement were studied for 
survival at 3 and 5 years. These were all patients 
who had not previously received cancer-directed 
treatment. Life-table methods based on full in­
tervals only were used to analyze survival. 
Adjustment for deaths from other causes was 
provided by computing the expected and relative 
survival rates.
The 5-year relative survival rates (% ) were 
60.2 ±  4.1 for the total group of 283 patients,
87.9 ±  4.5 for the 142 with localized disease and
44.9 ±  5.9 for the 118 with regional spread. Of 
the patients with disease that was either local­
ized or regional, 84% underwent total mastec­
tomy. The age of patients at entry did not differ 
from that of cases reported to the Quebec Tu­
mour Registry. The significant increase over 
time in the proportion of patients with localized 
disease would be expected to reduce the 
Quebec death rate from breast cancer in future 
if the better survival of these patients is not 
simply a function of earlier diagnosis.
Resume: La survie de 283 femmes atteintes de 
cancer du sein diagnostique a I'Hopital du Saint- 
Sacrement de 1965 a 1973 a ete etudiee par la 
methode actuarielle basee sur des intervalles 
annuels complets. L'ajustement pour les de- 
ces par autres causes a ete obtenu en calculant 
les taux de survie esperes et relatifs. Ces pa- 
tientes sont toutes celles qui n'avaient pas ante- 
rieurement repu de traitement anticancereux.
Le taux de survie relatif (% ) a 5 ans est 60.2 
±  4.1 pour le total des 283 patientes, 87.9 ±  
4.5 pour les 142 patientes atteintes d’un cancer 
localise et 44.9 ±  5.9 pour les 118 avec cancer 
regional. Dans ces deux dernieres categories, 
84% des patientes ont eu une mastectomie to- 
tale. L’age des malades a I'entree ne differe pas 
de celui des cas declares au Registre des 
Tumeurs du Quebec. L'accroissement significatif 
de la proportion des cas localises entre 1965 
et 1973 devrait reduire le taux de mortalite par
*From the department of surgery, H6pital du Saint-Sacrement, and the department of social and preventive medicine, Laval University, Quebec, Que.
Presented in part at the meeting of the Canadian Association of Clinical Surgeons, Quebec, Que., Mar. 14, 1975.
Reprint requests to: Dr. L. Deschenes, Department of surgery, Hopital du Saint-Sacrement, 1050, Che- min Ste-Foy, Quebec, PQ. K1S 4L8.
cancer du sein au Quebec si la meilleure survie 
de ces patientes n'est pas simplement fonction 
d'un diagnostic plus precoce.
A lthough  there have been a number of 
reports of survival rates for women with 
breast cancer, those from surgical depart­
ments have usually focused on the compa­
rison of results of treatment in specified 
stages of the disease. The purpose of this 
paper is to describe the overall survival of 
283 women with breast cancer.
M ethods
Sources of Data and Period of Study
Records relating to all women in whom 
breast cancer was first diagnosed from Jan. 
15, 1965 through Sept. 1, 1973 at l’Hopi- 
tal du Saint-Sacrement, Quebec City were 
reviewed, as were records of the tumour 
clinic supervising follow-up and records 
of the department of histopathology. Death 
certificates filed at the Quebec population 
registry for patients reported to have died 
were also reviewed.
Follow-up observations continued through 
Aug. 31, 1974. All patients not known to 
have died were contacted at the close of 
the study. There were no losses to follow-up.
Criteria for Entry into Study
Entry into the study was restricted to pa­
tients who had not previously received any 
treatment for cancer, in accordance with the 
criteria used by the End Results Group of 
the US National Cancer Institute.1
Survival
Survival was measured from the date of 
the first hospitalization during which breast 
cancer was diagnosed.2 Life-table methods3 
based on full intervals only4 were used to 
analyze survival. To avoid biases linked 
with incomplete intervals, patients due to 
withdraw because of the end of the study 
were removed at the start of the interval 
and not during it, as recommended by Drolette.4
Deaths from all causes were included in 
the analysis in accordance with the state­
ment of Paterson, Tod and Russell,3 cited
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TABLE I .__Survival* for 283 W omen with B reast C ancer (all Stages)
Y e a r
a fte r
e n tr y
N o . o f  
p a tie n ts  
alive  at 
s ta r t o f  
in te rv a l
N o .  o f  
p a tie n ts  
w ith d r a w n  
live a t s ta r t
o f
in te rv a l
N o . o f  
p a tie n ts  
u n d e r  
observa tion  
d u r in g  
in terva l  
(0)
N o .  o f  
p a tie n ts  
d y in g  in  
in te rva l
(D)
P r o b a b i l i ty  o f  
d ea th  i n  
in te rv a l  
(<? = D/O)
P r o b a b i l i ty
o f
s u r v iv a l  
(P  =  1 -  Q)
C u m u la t iv e  
p r o b a b il i ty  
o f  s u r v iv a l  
to s ta r t
o f
in te rv a l
0
1
2
3
4
5
283
249
191
127
%
68
34
44
23
19
283
215
147
104
77
34
24
20
8
9
0.120
0.112
0.136
0.077
0.117
0.880
0.888
0.864
0.923
0.883
1
0.880
0.781
0.675
0.623
0.550
*Rates computed by the actuarial method and based on full intervals.
by Ederer, Axtell and Cutler6 that “no fig­
ures which depend on opinion as to the 
cause of death . . .  can be accepted as com­
pletely reliable”. The necessary adjustment 
for mortality from causes other than breast 
cancer and for association between age and 
risk of death from other causes was provided 
by computing the relative survival rate.7
The relative survival rate is defined as 
the ratio of the observed survival rate 
in a group of patients during a specified 
period of time to the survival rate expected 
over the same period in a group of persons 
from the general population with the same 
age and sex distribution as the patients.6 The 
expected survival rates were computed with 
the exact method6 from the 1970 to 1972 
sex-specific life-tables8 for the population 
of the Quebec City region; 88% of the 
patients in this series came from this region.
The standard error of the observed sur­
vival rate was computed from Greenwood’s 
formula.6 The standard error of the relative 
survival rate was obtained by dividing the 
standard error of the observed survival rate 
by the expected rate.6
Assessment of the Extent of Disease
Assessment of the extent of disease was 
based on all information available at first 
hospital discharge.1 Disease was classified 
in three categories in conformity with the 
classification adopted by the Connecticut 
Cancer Registry16 and the US End Results 
Program:11 localized (no evidence of spread 
of tumour beyond the breast), regional 
(evidence of spread to axillary or supra­
clavicular lymph nodes, ipsilateral skin or 
chest wall) and distant (evidence of meta- 
stases beyond the region).
R e s u l t s
Of the 283 patients included in the study, 
142 were considered to have localized breast 
cancer, 118 to have evidence of regional 
spread and 23 to have distant metastases. 
Among the patients with localized and re­
gional disease, the diagnosis was confirmed 
microscopically in 98.5% .
Survival for the 283 patients is sum­
marized in Table I. The probability of death 
was highest during the 3rd year after entry. 
The trends of the observed and expected 
cumulative survival rates are compared in 
Fig. 1. The two curves are greatly divergent, 
leading to a 5-year observed cumulative 
survival rate of 55% and an expected sur­
vival rate of 91.3%.
The 3- and 5-year relative survival rates 
with their standard errors appear in Table 
II together with the rates reported in the 
most recent studies, in which the same cri­
teria for admission of patients were used.^
The well-known highly significant dif-
v.
Fig. 1.—Observed and expected survival rates, 
1965 to 1973, all stages.
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TABLE II. R elative Survival Rates at 3 and 5 Years for Breast Cancer Patients (all Stages) 
___________ Obtained in P resent Study and in F our Recent Studies*
Period of 
entry
Relative survival rate, %
Study No. of patients 3-year 3-year
Saint-Sacrement (Quebec) 
US End Results Program.
Boston................
Glamorgan (Wales)..........
Tokyo...............
........................... 1965 —  1973
/  1960 —  1964 
.........................  \  1965 —  1969
.......................... 1965 —  1967
283
13 828
14 911 
732 
701 
829
70.9  ±  3.3
73
72
75.3  ±  1.9
66.4  ±  1.9 
85.6  ±  1.3
60.2  ±  4.1
63
62 f
♦Sources: Morrison et al.2 and US Department of Health, Education and Welfare13 
^ c t i o n  based on the assumption that survival after 3 years is as good as that for patients diagnosed in
together, the 5-year observed and relative 
survival rates were 59.7 ±  3.9 and 65 1 ±  
4.2.
The proportion of all patients with local­
ized disease increased significantly over 
calendar time from 35.7% in the period 
1965 through 1969 to 64.3% in the period 
1970 through 1973 (Table III). This trend 
started in 1968, the proportion rising stead­
ily thereafter. Within each period, the pro­
portion of patients with breast cancer that 
was assessed as localized decreased with age 
at entry.
The significantly lower median and mean 
ages at entry for women with localized dis­
ease is evident in Table IV. Also evident is 
the finding that the median and mean ages 
of patients at entry into our study were 
not significantly different from those of 
breast cancer cases reported to the Quebec 
Tumour Registry from 1967 through 
1972.12
The distribution of treatment methods 
among the 260 patients with localized or 
regional disease is given in Table V. The 
majority were treated by total mastectomy. 
Only 28 (11%) of patients underwent ra-
TABLE III.—D istribution of Breast Cancer Patients According to Age at Entry, Period of Entry
and E xtent of D isease
Age at entry
Period of entry Extent of disease
<45 45 —  54 55 --  64 65 + Total
n % n % n % n % n %
1965 to 1969 . . . . Localized 16 48.5 14 38.9 n 31.4 9 25.0 50 35.7Regional 15 45.4 21 58.3 19 54.3 21 58.3 76 54.3Distant 2 6.1 1 2.8 5 14.3 6 16.7 14 10.0Total 33 100.0 36 100.0 35 100.0 36 100.0 140 100.0
1970 to 1973 . . . Localized 21 72.4 25 65.8 28 66.7 18 52.9 92 64.3Regional 6 20.7 10 26.3 12 28.5 14 14.2 42 29.4Distant 2 6.9 3 7.9 2 4.8 2 5.9 9 6.3Total 29 100.0 38 100.0 42 100.0 34 100.0 143 100.0
ference in survival between patients with 
localized disease and those with evidence of 
regional spread is illustrated in Fig. 2. The 
5-year observed and relative survival rates 
(%), adjusted to the age distribution of the 
total group of patients, were respectively 
82.1 ±  4.2 and 87.9 ±  4.5 for patients with 
localized breast cancer versus 40.7 ±  5.2 
and 44.9 ±  5.9 for those with regional di­
sease (but these last two rates have rather 
large standard errors and, therefore, are not 
stable). For localized and regional cases
7.
Fig. 2.—Relative survival rates, 1965 to 1973, 
localized, regional and all stages.
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dical mastectomy; these were treated mostly 
in the early part of the study period (1965 
and 1966). Of the patients with evidence 
of regional spread of the lesion, 91 under­
went total mastectomy, 17 a radical mastec­
tomy, 7 had nonsurgical treatment and 3 
refused treatment. The disease in these 118 
patients was considered to be regional be­
cause of skin involvement in 14 instances 
(11.9%), clinical involvement of axillary or 
supraclavicular lymph nodes, or both, in 51 
instances (43.2%), clinical and pathologic 
involvement of lymph nodes in 30 instances 
(25.4%) and pathologic involvement of 
lymph nodes only in 23 instances (19.5%).
Cobalt was used alone in 2% of patients 
and as an adjunct to surgical treatment in 
85%. The total radiation dose used post- 
operatively on the axillary, supraclavicular 
and internal mammary lymph node chains 
was 5000 rads delivered over 5 weeks with 
5 sessions per week of 200 rads at each 
session.
Discussion
The 3- and 5-year relative survival rates 
(%) for our patients (70.9 ±  3.3 and 60.2 
±  4.1) are similar to those of the US End 
Results Program for patients with all stages 
of breast cancer diagnosed in 1960 to 1964 
and 1965 to 1969 (72 and 62).13 In an in­
ternational study conducted in the mid- 
1960s, the 3-year relative survival rates 
(%) were 85.6 (Tokyo), 75.3 (Boston) and 
66.4 (Glamorgan, Wales).2 According to 
Morrison and colleagues,2 these significant 
differences in survival are not explained by 
the differences in extent of disease.
The rather low survival rate for the pa­
tients with regional spread may possibly re­
flect some degree of misclassification, for 
two reasons. First, the McWhirter tech-
TABLE V.—D istribution of Breast Cancer 
T reatment* for Localized and R egional Cases
Treatm ent
N o. (an d  
% ) of p a tie n ts
Total mastectomy. .. 219 (84.2)
+  radiation............ 201
Alone....................... 18
Radical mastectomy. 28 (10.8)
+  radiation............ 18
Alone....................... 10
Tumorectomy (with
or without radia-
tion)........................ 3 (1.2)
Radiation only.......... 5 (1.9)
Other (medical)......... 2 (0.7)
Refused....................... 3 (1.2)
Total................... 260 (100.0)
♦First course of treatment initiated within 6 mo of 
entry.
nique,14 which was used in the majority of 
the patients, does not lead to systematic exci­
sion and pathologic examination of axillary 
lymph nodes. This might results in classify­
ing mainly cases with clinical involvement 
of lymph nodes as regional. Second, modem 
techniques for the detection of distant me- 
tastases were not available in the early years 
of the present study, so that the disease in 
some patients with distant metastases may 
have been misclassified as regional.
Perhaps the most striking finding of this 
study is the increase in recent years in the 
proportion of patients diagnosed at the local­
ized stage. If this trend applies throughout 
the province of Quebec and if the better 
survival observed for these patients is real 
and not simply a function of earlier diag­
nosis, the age-adjusted annual death rate 
from breast cancer in Quebec should de­
crease in the future.
We acknowledge the help of Drs. Paul Auger, 
Robert Cote, Jean Couture and Claude Fortin of 
the department of surgery, Jeanette La Vertu and 
Pierrette Cote of the tumour clinic, and Michele 
Beliveau of the medical records section, Hopital 
du Saint-Sacrement; Dr. Jean-Marc Fredette of
TABLE IV —Median and Mean Ages at Entry for Patients in Study According to E xtent of 
D isease and for Breast Cancer Patients R eported to Quebec T umour R egistry (1967 to 1972)
P atien ts in  s tu dy
F em ale p a tie n ts  reported to 
Quebec T um our R egistry  
{1967 to 1972)
Localized  
(n — 142)
Regional 
(n = 118)
D ista n t
(n = 23)
A ll stages 
{N  =  283)
A ll  stages 
( N  =  9959*)
Median age (yr). . . .
Mean age (yr).........
Standard deviation..
53.5 
54.0
12.5
57.2
58.1
13.7
59.4
57.3
14.1
55.7
56.0
13.3
55.9
56.8
13.2
♦This total does not include 170 cases of unknown age.
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the Quebec Population Registry, Ministry of So­
cial Affairs; and Widna Morin, department of so­
cial and preventive medicine, Laval University.
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CUTANEOUS GANGRENE: A RARE COMPLICATION OF 
COUMARIN THERAPY*
M. SHNIDER, MD and C. R. D’SOUZA, MD, FRCS[C]
Summary: Sodium warfarin was administered to 
a 59-year-old woman with congestive cardiac 
failure and deep vein thrombosis. After 3 days 
of therapy the nipple and areola of the left 
breast became inflamed; the entire breast then 
became necrotic. Gangrene spread and a simple 
mastectomy was performed. The patient died 
from pulmonary embolism 1 day after operation. 
Histologic examination of the breast revealed 
thrombi in some of the arteries and veins. The 
etiology of this condition is obscure, and there 
is no known way of preventing or effectively 
treating the condition. Simple mastectomy or 
more conservative local excision recommended.
Resume: A une femme de 59 ans souffrant d’une 
insuffisance cardiaque et d'une thrombose vei- 
neuse profonde, nous avons administre de la 
warfarine sodique. Trois jours apres le debut 
de ce traitement, le mamelon et I’areole du 
sein gauche devinrent enflammes, puis le sein 
devint completement necrose. La gangrene s'e- 
tant repandue, nous avons pratique une mastec- 
tomie simple. La patiente est decedee le lende- 
main de I'operation d'une embolie pulmonaire. 
L'examen histologique du sein a revele des
*From the department of surgery, Flin Flon 
General Hospital, Flin Flon, Man.
Reprint requests to: Dr. M. Shnider, Depart­
ment of surgery, Flin Flon General Hospital, Flin 
Flon, MB R8A 1N2.
thrombi dans certaines veines et arteres. L'etio- 
logie de cette pathologie demeure obscure et 
on ne connait aucun moyen de la prevenir ou 
de la traiter efficacement. Une mastectomie 
simple ou une excision locale plus conservatrice 
est le traitement que nous recommandons.
The common complication of coumarin 
derivatives such as bishydroxycoumarin (di- 
cumarol) is bleeding, but a rare complica­
tion is cutaneous gangrene. Its occurrence 
is unpredictable and unrelated to dose, and 
its course is influenced neither by stopping 
nor continuing administration of the drug. 
Few cases of the condition have been re 
ported.1 The following is one such case.
Case R eport
A 59-year-old woman was admitted with 
sudden onset of dyspnea, constrictive retro­
sternal pain and edema of the feet. A diagnosis 
of congestive cardiac failure was made and 
digoxin and diuretics were given. Left calf 
tenderness and a positive Homan’s sign 10 days 
later led to the diagnosis of deep vein throm­
bosis of the left leg.
Treatment with sodium warfarin (Coumadin) 
was started and prothrombin times were meas­
ured daily (Table I). After 3 days of therapy 
the nipple and areola of the left breast ap-
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peared red and inflamed and a blister devel- 
oped. Sodium warfarin was stopped on the 3rd 
. day. The lesion became tender and then ne­
crotic over an area of 5 cm. The entire breast 
y  was inflamed and swollen to about twice its 
normal size. The necrotic tissue was excised 
3 days later under local anesthesia. The ne­
crotic area extended through the breast and 
down along the pectoral fascia. Cultures of the 
tissue did not grow any organisms. Treatment 
with hydrocortisone (Solucortef) by intramus- 
•v cular injection was started (100 mg lid) and 
continued for 1 week. The gangrene gradually 
spread’ and, in spite of her poor general condi­
tion, it was decided 10 days later to do a 
simple mastectomy. She died on the day after 
' j  operation from a massive pulmonary embolism.
Histologic examination of the breast revealed
- the following findings: The skin showed ex­
tensive changes; many of the small vascular
' spaces (venules) contained thrombi, as did 
some of the larger arteries and veins, a few 
vessels (mainly arteries) manifesting an acute
- *• inflammatory reaction; scattered through the 
* debris was a prominent cellular infiltration of
l  polymorphs and numerous eosinophils; some 
adnexal glands showed partial ischemic necrosis.
Discussion
Bishydroxycoumarin and congeners, used 
therapeutically to produce hypoprothrom- 
» a binemia, depress the vitamin K-dependent 
clotting mechanism through their effect on 
y  Factors II, VII, IX and X. The Quick one- 
stage prothrombin time is prolonged; it is 
maintained at a therapeutic level of 2.5 to 3 
times the normal.
The adverse effects of these drugs are 
* threefold: (a) hemorrhage of minor or ma­
jor extent from any tissue or organ; (b) sys­
temic reactions such as fever, nausea, diar­
rhea and alopecia; and (c) skin reactions. 
The skin reactions include ecchymosis and 
purpura due to hypoprothrombinemia; 
^  masculopapular, vesicular and urticarial
TABLE I.—Dose of Sodium Warfarin, P roi
eruptions; the “purple-toes” syndrome;2 and 
the rare necrosis—usually of the breasts, 
thighs and flanks.
Few cases of skin necrosis associated 
with use of coumarin derivatives have been 
reported in the English literature. Although 
Flood and associates3 in 1943 first de­
scribed a case of breast gangrene in a pa­
tient receiving bishydroxycoumarin they in­
terpreted the changes as being manifesta­
tions of thrombophlebitis migrans disse­
minata from which the patient suffered. 
Kipen4 in 1961 was the first to associate 
breast changes with sodium warfarin ther­
apy. By 1971 at least 150 cases of cuta­
neous necrosis had been reported, in 25 of 
which the breast was affected.5
Both bishydroxycoumarin and sodium 
warfarin have been implicated. Heparin 
alone has not produced this complication 
although it has been used frequently to in­
itiate anticoagulation.6
The condition usually affects middle-aged 
or elderly women.7 It begins between the 
3rd and 10th day of treatment; in 93% of 
cases it begins between the 3rd and 5th 
day.1 It is unaffected by discontinuance of 
coumarin congeners and, once therapy has 
been started, it progresses inexorably. Con­
tinuation of therapy after skin lesions have 
developed does not result in untoward re­
actions, new skin lesions, exacerbation of 
existing lesions, or impairment of healing.8 
As the present case indicates, there is no 
correlation between the prothrombin value 
and the appearance of the skin lesions9 (Ta­
ble I).
Clinically, the disorder affecting the 
breast is characterized by pain, redness, in­
duration and formation of bullae that con­
tain serosanguinous fluid. A well-demarcated 
eschar soon forms. Biopsy of the lesion at
rombin T ime and Onset of Clinical F eatures
-i Day of treatment
Sodium warfarin dose- 
{mg)
Prothrombin time 
(% of normal)
Preoperative 
clinical course
1 10 — —
2 5 32 —
Q 10 15 —
4 Nil 40 Erythema and blister, left nipple
R Nil 30 Erythema and blister
a Nil 26 Erythema and blister
7 Nil 40 Erythema and blister
g Nil 45 Frank gangrene
► 9 Nil 40 Excision
The Effect of
Trasy lol
in
Acute
Pancreatitis
* Results
C o u r s e  o f  il ln e s s
G r o u p  A  (T r a s y lo l) G r o u p  B (P la c e b o )
N o . % N o. %
M ild 3 0 5 6 .6 2 2 4 2  3
M o d e r a te 1 3 2 4 .5 9 1 7  3
S e v e r e 6 1 1 .3 8 1 5  4
D ie d 4 7 .5 1 3 2 5 .0
T o ta l 5 3 9 9 .9 5 2 1 0 0 .0
e x te n t^  W3S shown to reduce mortality in acute pancreatitis to a significant
Placeb0................................................ 25.0% Mortality
Trasylol®...............................................  7.5% Mortality
“ Because the number of deaths were reduced, the spectrum of the disease 
as a whole was altered.” *
Trapnell’s recent double-blind clinical trial 
involving 105 patients confirmed the 
effectiveness of Trasylol in acute 
pancreatitis. In addition to reducing 
mortality and altering the spectrum of the 
disease, Trasylol largely abolished the usual 
effect of increasing age in this condition. 
Trasylol should be given concurrently with 
usual measures for the treatment of 
pancreatitis, such as pain relief, 
fasting, gastric suction, etc. “ It 
(Trasylol) can therefore now be 
regarded as a drug which is both 
effective and beneficial in the 
treatment of acute pancreatitis.” *
*Trapnell, J.E. et al, British 
J. Surg., March 1974.
The Effect of
Trasylol
in
Hyperfibrinolytic
Hemorrhages
A
Trasylol, in its role as an Synthetic antifibrinolytic
antifibrinolytic agent, inhibits agents inhibit only the
both plasmin and the plasminogen activator,
plasminogen activator.
Trasylol is indicated for primary and generalized, secondary 
hyperfibrinolytic hemorrhages with and without the shock 
syndrome. Secondary hyperfibrinolysis following 
intravascular clotting may require heparin and/or 
fibrinogen replacement in addition to Trasylol. 
With Trasylol, the antifibrinolytic agent with 
simultaneous anti-coagulant (anti-thromboplastic) 
effect, there will not be a dangerous shift 
in the equilibrium between 
the clotting and the lysis system 
in favour of coagulation. 
Synthetic antifibrinolytics 
are contraindicated if there is 
evidence of active intravascular 
coagulation. Trasylol is indicated 
in all cases of hyperfibrinolysis, 
whether a differential diagnosis 
has been made or not.
FBA Pharmaceuticals Ltd.
Distributed by:
Boehringer Ingelheim (Canada) Ltd.
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Trasylol
•  increases the chances 
of survival in acute 
pancreatitis
•  prevents the enzymatic 
release of toxic 
polypeptides and kinins
•  stops hyperfibrinolytic 
hemorrhage
Indications and Dosage
Hyperfibrinolytic Hemorrhage 
These co n d ition s  o ccu r in su rgery , 
including open heart surgery, prostatic 
surgery and pathological obs te trica l 
bleeding conditions, such as in abruptio 
placentae.
Initial dosage: 200,000 — 500,000 K.I.U. 
of which 200,000 K.I.U. should be given 
by intravenous injection (a t a rate not to 
exceed 5 ml per minute), the rest if neces­
sary by slow  infusion. Adm in istra tion 
should  be continued up to 1,000,000 
K.I.U. per day until the hemorrhage has 
been arrested.
Pancreatitis
Initial dosage: 100,000 — 200,000 K.I.U. 
to be followed by 100,000 K.I.U. every 
six hours fo r a period of 4-5 days. The 
drug is administered either by intraven­
ous in jection (at a rate not to exceed 5 
ml per minute) or by slow infusion. 
Warnings and Precautions 
Trasylol is a polypeptide and thus may 
act as an antigen. Although adverse reac­
tions due to hypersensitivity have been 
described infrequently, this possibility 
should always be kept in mind. In patients 
w ith a h is to ry  of hypersensitiv ity, the 
usual precautions for the prevention and 
arrest of a lle rg ic  reactions should  be 
observed prior to the adm inistration of 
Trasylol.
Availability
Trasylol (aprotinin) is available in 10 ml 
am puls  co n ta in ing  100,000 K.I.U . in 
boxes of 5 ampuls.
Trasylol® Product Monograph is available 
on request.
The object of
Trasylol:
Control of proteolytic enzymes.
FBA Pharmaceuticals Ltd. ( )
Distributed by: vzfy
Boehringer Ingelheim (Canada) Ltd.
2121 Trans Canada Highway, Dorval, P.Q. H9P1J3
this time reveals necrotizing arteritis, venous 
thrombosis and severe necrosis; these 
changes differentiate the condition from sim­
ple hemorrhage in tissues. Extramammary 
lesions tend to affect thighs and gluteal re­
gion; face, hands and feet are seldom in­
volved. 10 The etiology of the condition is 
obscure. Allergic reaction, hypersensitivity 
and toxic reactions have been proposed as 
the mechanisms of injury.11- 12
No way is known of predicting, prevent­
ing or effectively treating the condition. 
Steroids, heparin, 13 local hypothermia, and 
sympathetic nerve blocks are equally inef­
fective. Simple mastectomy or more con­
servative local excision5 is recommended.
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INCREASING OPERABILITY AND SURVIVAL WITH INTRA-AORTIC
BALLOON PUMP ASSIST*
B S GOLDMAN M D, FRCS[C], FA C S,t J. GUNSTENSEN, M D, FRCS[C],{ B- S B W  GILBERT MD,§ T . C .  KELLY,If H .SC U L L Y ^M D  FRCSJGLJI W. G. WILLIAMS, MD, FRCS[C] and A. G. ADELM AN, MD, FRCP[C]
Summary: Intra-aortic balloon pump assist
(IABPA) was used over a 12-month period in the 
management of 41 patients: 5 patients with 
complications of myocardial infarction in shock 
whose circulation was supported by IABPA be­
fore operation immediately after angiogra­
phic and hemodynamic study (group 1): 14
patients with postcardiotomy low-output state 
who could not be weaned from cardiopulmonary 
bypass and required IABPA circulatory support 
either in the operating room or in the intensive 
care area (group 2); 19 patients with severe 
myocardial ischemia and unstable circulation in 
whom IABPA was instituted either before angio­
graphy or before saphenous vein bypass oper­
ation (group 3); and 3 patients with severe left 
ventricular dysfunction and left ventricular hy­
pertrophy due to aortic valve or coronary artery 
disease, or both, in whom IABPA was used 
before, during and after cardiopulmonary bypass 
and a corrective operative procedure (group 4). 
Survival rates for patients in these groups were 
2/5, 8/14, 18/19 and 2/3 respectively (overall sur­
vival, 73%). IABPA may increase the post­
operative survival of certain high-risk patients 
with poor left ventricular function due to val­
vular disease or coronary artery disease, or 
both. The survival of patients with severe myo­
cardial ischemia and complicated myocardial in­
farction is improved by IABPA, early angiography
*From the divisions of cardiovascular surgery and cardiology, Toronto General Hospital, Toronto, 
Ont.
Presented at the 46th annual session of the Amer­ican Heart Association, Dallas, TX, November 
1974.
Supported in part by the Ontario Heart Founda­tion and the Theodore Richmond Cardiovascular 
Fund.
f  Assistant professor, department of surgery, 
University of Toronto.
{Clinical fellow, division of cardiovascular sur­
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§Clinical fellow, division of cardiology, Toronto 
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^Biomedical technician, Toronto General Hospital. 
|| Lecturer, department of surgery, University of 
Toronto.
**Assistant professor, department of medicine, 
University of Toronto.
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and appropriate surgical correction. Left ventri­
cular ejection fraction and the estimate of 
subendocardial coronary flow by the ratio of the 
diastolic pressure time index to the tension time 
index appear to be significant in identifying pa­
tients who may benefit from the use of IABPA.
Resume: Le bailon-pompe intra-aortique (BPIA) a 
ete utilise pendant une periode de 12 mois pour 
traiter 41 patients: le groupe 1 compose de 5 
malades souffrant de complications d'un infarc- 
tus du myocarde et en etat de choc; le BPIA 
a aide la circulation avant I’operation et imme- 
diatement apres angiographe et etude de I'hemo- 
dynamique (un des malades, inoperable, est 
decede). Le groupe comprenait 14 malades qui, 
apres cardiotomie, presentaient un faible debit 
cardiaque et qui ne pouvaient se passer de la 
derivation cardiopulmonaire; on a done utilise le 
soutien circulatoire fourni par le BPIA, soit dans 
la salle d'operation, soit dans I'unite des soins 
intensifs. Le groupe 3 etait compose de 19 ma­
lades, souffrant d'une severe ischemie du myo­
carde, et d’une circulation instable; chez ces ma­
lades, on a eu recours au BPIA soit avant I'angio- 
graphie, soit avant I'operation de pontage de la 
veine saphene. Quant au groupe 4, il comprenait 
trois malades souffrant d'un severe dysfonction 
nement du ventricule gauche et d'une hyper- 
trophie dudit ventricule, attribuable a une valvu- 
lopathie aortique ou a une insuffisance corona- 
rienne (ou aux deux pathologies) et chez lesquels 
on a utilise le BPIA avant, pendant et apres la 
derivation cardiopulmonaire et I'operation cor- 
rectrice. Chez les malades de ces groupes, le 
taux de survie a ete de 2/5, 8/14, 18/19 et 2/3 
respectivement (survie globale de 73%). Le BPIA 
permet d'augmenter la survie postoperatoire de 
certains malades dont le risque est particulie- 
rement eleve et dont la fonction du ventricule 
gauche est mediocre, par valvulopathie ou par 
une deficience coronarienne ou par les deux. Le 
BPIA peut ameliorer la survie de malades souf­
frant d’une severe ischemie du myocarde et d'un 
infarctus du myocarde complique, cet appareil 
facilitant une angiographie precoce et la correc­
tion chirurgicale appropriee. Le rapport de la 
pulsion du ventricule gauche a la pulsion diasto- 
lique est un indice precieux qui permet d’eva- 
luer dans quelle mesure la circulation corona­
rienne est amelioree et, par consequent de re- 
connaitre les personnes qui sont susceptibles 
de beneficier du bailon-pompe intra-aortique.
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Abbreviations
AMI Acute myocardial infarction
ACB Aortocoronary bypass
AVR Aortic valve replacement
Cl Cardiac index
DPTI/TTI Diastolic pressure time index
/tension time index
EF Ejection fraction
IABPA Intra-aortic balloon pump
assist
LVF Left ventricular function
MVR Mitral valve replacement
OR Operating room
RR Recovery room
TGV Transposition of great vessels
VF Ventricular fibrillation
Intra-aortic balloon pump assist (IABPA) 
has been moderately successful in the man­
agement of cardiogenic shock due to acute 
myocardial infarction (AMI).1' 2 Temporary 
improvement and stability of the altered 
hemodynamic state permits diagnostic evalu­
ation and surgical therapy when appropri­
ate.2- 4 IABPA is also useful in providing 
circulatory assistance in patients with the 
low-output state that may follow cardiac 
surgery.:> It is being used increasingly in the 
management of refractory or recurrent myo­
cardial ischemia with relief of ischemic 
pain,0 and angiographic and hemodynamic 
investigative procedures and myocardial re­
vascularization can then be accomplished.7 
The physiologic benefits of balloon pump 
counterpulsation stem from decreased left 
ventricular afterload and thus decreased 
systolic work with a consequent decrease in 
myocardial oxygen demand.8 Diastolic aug­
mentation increases aortic root pressure with 
a potential increase in coronary flow.9 In 
this paper we review our experience with 
intra-aortic balloon pumping using the 
AVCO console*.
*Kontron Scientific Ltd., Montreal, Que.
Patients and Methods
Details of Patient Groups
In the 12-month period from Oct. 1, 
1973 to Oct. 1, 1974, 44 patients were con­
sidered candidates for IABPA. IABPA was 
used in 41, in four groups (Table I): in 
5 who had life-threatening complications of 
extensive AMI (group 1); in 14 patients 
who could not be weaned from cardiopul­
monary bypass or who had low-output states 
in the recovery room after cardiovascular 
surgery (group 2); and in 22 patients with 
severe coronary artery insufficiency (19 
with coronary artery disease [group 3] and 
3 with combined aortic valve and coronary 
artery disease [group 4]), prophylactically, 
for circulatory support just before operation, 
support being continued during operation 
and the postoperative period. In three other 
patients, who subsequently died, the balloon 
catheter could not be inserted because of 
extensive atherosclerosis in the iliac arteries 
and abdominal aorta; one had cardiogenic 
shock, a second had severe coronary artery 
insufficiency and the third had a low-output 
state postoperatively.
Group 1.— Myocardial infarction in all 
five patients was documented by serial elec­
trocardiographic and enzyme changes. In 
four, cardiogenic shock developed 12 to 24 
hours after infarction, as evidenced by ar­
terial systolic pressures below 80 mm Hg, 
a urine output of less than 20 ml/h, vary­
ing degrees of mental obtundation and peri­
pheral vasoconstriction (Table II). Although 
all four received medical therapy to correct 
hypoxia, acidosis or hypovolemia as well as 
inotropic and vasopressor agents when in­
dicated, their clinical condition was deterior­
ating when IABPA was instituted. Heart 
catheterization was then carried out and 
three of these four patients subsequently 
underwent operation. In the fifth patient of 
this group recurrent attacks of ventricular 
tachycardia had continued despite intensive
TABLE I.—Use of Intra-aortic Balloon Pump 
Group no. and diagnostic category
1 Complicated myocardial infarction........................
2 Postcardiotomy low output....................................
3 Severe coronary insufficiency.................................
4 Preoperative circulatory support...........................
Total...............................................................
Assist According to Patient Group, and Survival 
No. of patients No. of patients surviving
5 2
14 8
19 18
3 2
41 30 (73%)
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TABLE II.—Details of P atients in  Group 1 (M yocardial Infarction w ith  Complications)
LVF, 
grade 
I-IV
EF,
%
LVEDP, 
mm Hg
Coronary score 1:1 assist 
duration, 
minPatient
no. Age, sex
Previous
infarction Complication D P T I/T T I Preop. Poslop. Operation
Result
1
2
3
47. M 
45, M 
38, M
No
9, 7 yr 
earlier 
2 yr
Ventricular aneurysm, shock
Shock
Shock
IV
III
IV
9
41
7
16
25
43
0.56
1.07
0.50
7
11
10
7
8
Aneurys­
mectomy
ACB
Inoperable
192
70
144
Died
Alive
Balloon-dependent,
died
4
5
61, M 
56, M
No 
2 mo
M itral regurgitation, shock 
Ventricular aneurysm, 
recurrent VF
IV
III
9
9
16
22
0.56
1.03
8
11
8
8
MVR
Aneurys­
mectomy
36
70
Died
Alive
antiarrhythmic therapy and the balloon was 
inserted after angiography had visualized a 
t- resectable aneurysm.
Group 2 .— Of the 14 patients, 11 had 
undergone aortocoronary bypass (ACB), 2 
^  had received aortic valve replacement (AVR) 
and 1 had undergone corrective surgery for 
transposition of the great vessels (TGV) 
(Table III). Nine of them could not be 
v weaned from cardiopulmonary bypass and
the balloon was inserted before bypass 
was discontinued; in the other five the 
t balloon was inserted because a low-output
state persisted after operation. Low output 
in these five patients was characterized by a 
-1 systolic pressure below 80 mm Hg, urine 
output of less than 20 ml/h and varying 
degrees of peripheral vasoconstriction in 
spite of blood volume adjustment, assisted 
ventilation and pharmacologic therapy.
' t  Group 3 .—All 19 patients had unstable 
angina or severe coronary artery insufficiency 
* (Table IV). Of the 19, 10 were considered 
 ^- to have preinfarction angina in that they had 
severe prolonged episodes of chest pain with 
ischemic electrocardiographic changes at 
- y  rest. This pain was unrelieved by nitrites or 
propranolol and lasted longer than 20 min- 
, utes. The other nine patients were regarded 
as having crescendo angina because of re­
current attacks of angina at rest occurring 
with increasing frequency and severity to­
gether with ischemic electrocardiographic 
changes at rest. In these 9 patients, in con­
trast to the 10 with preinfarction angina,
the pain of crescendo angina was relieved 
by nitrites. All 19 patients were monitored 
in the coronary unit, where serial electro­
cardiograms and enzyme studies showed no 
evidence of infarction. In 2 of the 19 pa­
tients the balloon was inserted before heart 
catheterization, and in the other 17 it was 
introduced before ACB.
Group 4 .— The three patients had long­
standing aortic valve and coronary artery 
disease and were severely disabled with an­
gina and left heart failure (Table V). IABPA 
was instituted before operation for prophy­
lactic purposes.
Investigative Procedures
The patients in all four groups underwent 
right and retrograde left heart catheterization 
by the standard Seldinger technique. The 
cardiac output was measured by the Fick 
method. The pressures were recorded with 
Statham P23 transducers. Left ventricular 
angiograms were performed in the 30-de­
gree right anterior oblique projection by in­
jecting Renografin 76% (dose, 40 to 50 ml) 
into the left ventricle. Selective coronary 
cineangiograms were obtained by the Jud­
kins technique. The end-diastolic and end- 
systolic silhouettes were outlined from the 
cineangiograms and presented to a televi- 
sion/computer system for calculation of ven­
tricular volumes and ejection fractions (EF) 
by means of Simpson’s rule.10 Left ventri­
cular function (LVF) was also assessed sub­
jectively by two observers; it was graded I
TABLE I I I —Details of Patients in  G roup 2 (Postcardiotomy Low Output)
Age, sex
LVF grade, 
I-IV
EF, Cl
l/m inmm 2
LVEDP, 
mm Hg
Coronary score 
D P T I/T T I Preop. Postop. Operation Initiation min Results
2 ACB OR 47 Alive
1 ACB OR 24 Alive
2 ACB OR 31 Alive
2 ACB OR 36 Alive
1 ACB OR 72 AM I, alive
1 ACB OR 36 AM I, died
2 ACB OR 12 AM I, died
2 ACB RR 53 Alive
1 ACB RR 54 Alive
2 ACB RR 0.5 AM I, died
2 ACB RR 1 AM I, died
AVR OR 48 Alive
AVR, MVR RR 2.5 Died
TGV OR 0.5 Died
6
7
8 
910
11
12
1314
15
16
17
18 
19
50, M
60, F 
58, M 
45, M 
58, F 
50, F 
57, M
63, M
61, M
64, M 
35, M 
55, M 
33, M 
20, M
II
II
III 
II 
II 
III
II
III 
III
II
NA
NA
58
55
36
85
51
67
62
42
21
53
73
53
NA
NA
NA
2.61
2.91
3.53 
2.41 
3.85 
NA 
2.25 
1.89 
1.37 
4.61 
1.71
1.54 
NA
11
5
8
18
17
8
16
9
17
5
6 
55 
33 
20
1.15
0.62
0.54
0.76
0.37
0.63
0.67
0.54
0.65
1.80
0.93
0.83
0.78
NA
7
15
9
10
9
9
12
11
17
13
91
NA
NA
2
10
0
4
5
6 
10
3
12
5
2
1
NA
NA
NA — not assessed.
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TABLE IV. Details of Patients in Group 3 (Severe Coronary Artery Insufficiency)
Patient
no. Age, sex
LVF,
grade
I-IV
EF,
%
C l
l/min- 
mm2
Coronary score
LVED P ,
mm Hg D P T I / T T I  Preop. Postop.
1:1 assist 
duration, 
min Results
Preinfarction angina
20 55, M IV 13 NA 14 1.28 8 1 2421 42, F III 13 1.10 14 0.92 8 0 9222 45, M II 68 NA 13 0.70 6 2 423 53, M III 39 3.55 8 1.07 20 0 5224 50, M III 51 NA 29 0.66 10 1 4425 50, M II 79 3.35 7 0.30 11 8 36 AMI, alive26 58, M I 73 4.30 12 0.68 14 0 61 AMI, alive27 63, M III 48 NA 11 0.45 13 4 1128 53, M II 77 4.22 11 0.55 10 0 16829 56, F III 24 1.69 17 1.00 8 0 2 AML died
Crescendo angina
30 58, M III 40 3.84 20 0.54 9 5 9631 41, M III 34 2.70 25 1.00 15 3 2532 63, M IV 17 2.19 24 0.79 7 3 1833 57, M IV 29 4.30 11 1.05 11 7 3734 53, M III 40 3.02 11 1.02 11 9 7035 55, F III 36 2.70 10 0.83 12 8 1836 53, F IV 36 1.40 5 0.44 9 5 4837 57, M III 49 3.79 6 0.41 11 5 2738 54, M IV 8 1.83 30 0.80 12 3 45 Alive
NA — not assessed.
to IV— grade I being normal, grade II mild­
ly decreased, grade III moderately decreased 
and grade IV, severely decreased left ven­
tricular contraction. Coronary artery scores 
were calculated using a slightly modified 
Friesinger technique.11 Complete occlusion 
was graded V, narrowing of 90 to 99% was 
graded IV, multiple lesions with narrowing 
of 50 to 90% were graded III, narrowing 
of 50 to 70% was graded II and irregular­
ities with up to 50% narrowing were graded 
I. Double value was given for lesions in the 
left main system. Finally, the subendocar­
dial blood supply/demand relationship was 
estimated by Buckberg’s formula by calcul­
ating the ratio of the diastolic pressure time 
index to the tension time index (DPTI/ 
TTI).12 This is derived from planimetry of 
the areas under the left ventricular and 
aortic pressure tracings. In all 41 patients the 
intra-aortic balloon was inserted through 
the common femoral artery using techniques 
previously described.3 Balloon inflation and 
deflation was triggered from surface elec­
trocardiograms and was adjusted to produce 
maximum reduction in aortic systolic pres­
sure with maximum diastolic augmentation.
During cardiopulmonary bypass the bal­
loon catheter was inflated and deflated by 
means of an external artificial pacemaker.
This converted the mean flow of cardiopul­
monary bypass to a phasic pattern. The 
degree of pulsatile flow could be altered by 
Changes in the balloon volume (Fig. 1). 
Whenever technically possible, saphenous 
vein bypass graft flow was measured by an 
electromagnetic flowmeter both on and off 
intra-aortic balloon counterpulsation.
R esults
Group 1
All five patients had elevated end-dia­
stolic pressures, decreased ejection fractions 
and severe left ventricular dysfunction. 
Results are summarized in Table II. Patient 
3, whose condition was considered inoper­
able, was dependent on the balloon and died 
150-1
50-
10ml 20 ml
0 J
F'g- 1.—Pulsatile systemic flow obtained during 
extracorporeal perfusion with simultaneous IABPA 
and different balloon volumes. Alterations in bal­
loon volume (10, 0 and 20 ml) alter degree of 
pulsatile flow. Balloon is triggered by square 
wave impulse from artificial external pacemaker.
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on the 8th day, after inadvertent kinking 
and rupture of the balloon catheter at the 
groin during a period of restlessness. Pa­
tients 1 and 4 died after operation, one 
from an intractable cardiac arrhythmia and 
one from a noncardiac complication (tra­
cheal necrosis) after successful weaning from 
balloon support.
Group 2
Of the 14 patients 8 survived (Table III). 
It was not always possible to determine why 
the patient could not be weaned from car­
diopulmonary bypass or a low-output state 
after cardiac repair. In most instances, this 
was presumed to be due to myocardial in­
jury from prolonged anoxic arrest, inade­
quate revascularization or intraoperative 
infarction. Survival was slightly higher when 
IABPA was used in weaning from cardio­
pulmonary bypass than when its application 
was delayed (Table III). Of the nine pa­
tients in whom the balloon was inserted 
in the operating room (OR) at the end of 
cardiopulmonary bypass six survived, com­
pared with two of five patients in whom bal­
loon support was instituted in the recovery 
room (RR) after an attempt to correct the 
low-output state by traditional means. Five 
patients sustained myocardial infarction pe- 
rioperatively before IABPA was initiated 
and four of these patients died.
Of the 14 patients in this group 11 had 
undergone operation for coronary artery 
disease with stable angina and were not con­
sidered to be at increased risk. In seven of 
them DPTI/TTI ratios were less than 0.7, 
and in two, EFs were less than 40%. In a 
random group of 16 patients with stable an­
gina who underwent uneventful saphenous 
vein bypass surgery DPTI/TTI ratios ex­
ceeded 0.7 and the left ventricular EFs 
were greater than 40% (Fig. 2a).
Group 3
Among the 19 patients the EF was 40% 
or less in 12 and D PTI/TTI ratios of 
0.7 or less were demonstrated in 9 (Table 
IV) (Fig. 2b). In two patients there were 
low EFs and low DPTI/TTI ratios. In 
patient 29, in whom general anesthesia was 
induced before the balloon was inserted, the 
blood pressure decreased precipitously be­
fore balloon pumping could be commenced.
•  SURVIVORS
01
60
•  SURVIVORS 
o DEATH
os
lzt 40
20 -
0.2 0.4
i ____ 1__
0.6 0.7 0.8 1.0
_J_______I—
1.2 1.4
DPTI/TTI
Fig. 2b
Fig. 2.—Plots of left ventricular EF versus 
DPTI/TTI ratio (solid circles, survival; open 
circles, death), (a) Random group of 16 patients 
with stable angina who underwent saphenous vein 
bypass; all had evidence o f good left ventricular 
function and subendocardial flow and none re­
quired IABPA. (b) Group o f  19 patients with un­
stable angina who underwent IABPA and myo­
cardial revascularization; illustrates that most had 
either poor ventricular function or impaired sub­
endocardial blood flow.
Although resuscitation was effected and 
ACB to the anterior descending coronary 
artery was performed, it was not possible to 
wean this patient despite IABPA.
Group 4
All three patients had aortic valve steno­
sis, concomitant coronary artery disease, 
left ventricular dysfunction and low D PT I/ 
TTI indices (Table V). These patients were 
considered extremely high risks and in fact 
two of them had previously been denied 
surgery. Patients 39 and 40 underwent AVR 
alone. Patient 41 underwent AVR and 
double saphenous vein bypass grafting 
but died from severe aortic regurgitation, 
a calcific annular plaque preventing the 
ball of the prosthesis from seating. With
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diastolic augmentation in progress the result­
ant aortic regurgitation proved fatal.
Other Complications
In the entire series of 41 patients there 
were only two other complications related 
to the use of the balloon. One was mild 
claudication that developed in the limb used 
for insertion of the balloon in a patient 
who had been successfully treated for car­
diogenic shock after myocardial infarction. 
The other complication was the kinking of 
the balloon catheter in patient 3.
Saphenous Vein Bypass Blood Flow
In those patients in whom measurement 
was possible, a distinct increase in blood 
flow in the saphenous vein/coronary artery 
bypass was inevitably noted.
D iscussion
Intra-aortic balloon pumping produces 
a favourable hemodynamic response for 
patients in cardiogenic shock resulting from 
AMI and by itself leads to a modest in­
crease in survival.1' 2 Further improvement 
in survival may be achieved by vigorous sur­
gical therapy after hemodynamic stabil­
ization and angiographic study.3- 4 Post­
operative cardiogenic shock may be related 
to inadequate surgical repair, surgical mis­
adventure or prolonged anoxic arrest. 
IABPA has been successful in this situation, 
particularly when applied early, for wean­
ing from cardiopulmonary bypass in the 
operating room.13
The management of acute, severe coro­
nary artery insufficiency has developed ap­
preciably since the introduction of the 
saphenous vein bypass operation. However, 
despite early reports from randomized trials, 
there is at present no clear indication that 
medical or surgical therapy is unequivocally 
superior in terms of prevention of myocar­
dial necrosis or ultimate survival.14- 15 
Gazes and his colleagues16 have suggested 
that there is a high mortality for a specific 
subgroup of patients with “preinfarction
states”, but the literature gives no clear de­
finition of comparable patient groups.
None the less there is an obvious trend 
to early investigation and early myocardial 
revascularization for patients with severe 
coronary artery insufficiency.17- 18 The 
degree of left ventricular dysfunction rather 
than the severity of myocardial ischemia 
may be the limiting factor in survival from 
coronary artery surgery. Despite successful 
revascularization it is acknowledged that the 
long-term result in these patients is un­
known.
In an early review of experience with 
unstable angina, our group found a mortal­
ity rate of zero for patients with crescendo 
angina and adequate left ventricular func­
tion undergoing saphenous vein bypass 
operation; however, 12 of 16 patients oper­
ated on after prolonged medical therapy 
for recurrent acute coronary insufficiency 
(preinfarction angina) died, and histopathol­
ogic evidence of subendocardial necrosis 
was correlated with low preoperative DPTI/ 
TTI ratios.19 Left ventricular subendocar­
dial necrosis may account for 50 to 90% 
of postoperative deaths, especially in pa­
tients with coronary artery disease, left 
ventricular dysfunction, hypertrophy or 
aortic stenosis with high valvular gradi­
ents.20 In the presence of normal coronary 
arteries, subendocardial flow potential is 
reflected in the supply/demand equation, 
D PT I/T T I.12 An analysis of this present 
series indicates that this ratio may be of 
value in evaluating patients with coronary 
artery disease when considered in conjunc­
tion with left ventricular EF (Fig. 2). Com­
parative hemodynamic evaluations for both 
EF and DPTI/TTI in patients requiring 
balloon support before or after ACB are 
noted in Table VI.
Low mean pressure during cardiopul­
monary bypass, ventricular fibrillation elec­
trically induced and maintained, severe 
muscle hypertrophy, prolonged anoxic ar­
rest and, of course, preoperative evidence 
of subendocardial ischemia may all contri-
TABLE V.—Details of Patients in Group 4 (Preoperative IAPBA)
P a tie n t L V F ,  grade E F , C l , L V E D P ,
C o ro n a ry  score
A tr io v e n tr ic u la r  
gra d ien t, m m  H g
no. A g e , sex I - I V % l / m i n - m m 2 m m  H g D P T I / T T I P re o p . P o s to p . O p era tio n R e su lts
39
40
41
57, M 
52, M 
52, M
IV
IV
IV
40
34
30
0.55
2.66
3.21
42
26
8
0.49
0.29
0.35
7
2
6
7
2
0
AVR
AVR
AVR, 2ACB
100
52
70
Alive
Alive
Died
r
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TABLE VI.—Comparative Hemodynamic E valuation of P atients with Angina Undergoing Saphe­
nous Vein  Bypass Operation
Variable
Low EF ($  40%)...............................
Low DPTI/TTI ($  0.70).................
Low EF +  low D PTI/T TI..............
Neither low EF nor low DPTI/TTI
IABPA use and no. of patients
Preoperative Postoperative
Preinfarction Crescendo
Stable anginaangina angina
(M = 10) (n = 9) (n =  11)
4 8 2
6 3 7
0 2 2
0 0 4
bute to poor subendocardial perfusion with 
ultimate myocardial necrosis.19 IABPA re­
duces the TTI and augments the DPTI. As 
well, left ventricular systolic unloading will 
reduce diastolic pressure and volume, which 
contributes to intramyocardial pressure 
gradients that impair subendocardial flow 
(Fig. 3). IABPA may open dormant inter­
coronary collaterals,21' 22 increase flow 
through stenotic coronary arteries23 and, 
by converting mean extracorporeal bypass 
flow to a pulsatile wave form,24 may 
provide more uniform myocardial perfusion
75-
50-
25-
0
75-
5 0 -
25-
0
Fig. 3.—Changes in coronary blood flow/left 
ventricular myocardial demand ratio in patient 
in cardiogenic shock from acute myocardial in­
farction. Note improvement in ratio after in­
stitution of IABPA. Upper panel illustrates tracing 
when patient off IABPA, DPTI/TTI =  0.67; 
lower panel illustrates tracing when IABPA was 
in effect, DPTI/TTI =  1.95. Hatched area =  
TTI; stippled area =  DPTI.
or protection of areas not revascularized by 
saphenous vein grafting.
Use of the intra-aortic balloon pump has 
been relatively free of complications and 
well tolerated by patients in whom the post­
operative course has been smooth. Tech­
nical management by intensive care nurses 
and a supervisory technician has not been 
a problem and thus it is reasonable to ad­
vocate wider application and general use 
of this device. In our experience, the phy­
siologic benefits of IABPA have allowed us 
to increase the survival of patients with 
severe coronary artery insufficiency under­
going operation and increase the operability 
of certain high-risk patients with evidence 
of severe left ventricular dysfunction and 
poor subendocardial perfusion.
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when shock 
threatens 
the lung
Abstract visualization of lung tissue
• preserves 
lysosome and 
cell membranes, 
thereby preventing 
the release of destruc­
tive lysosomal enzymes3
• preserves platelets 
thereby reducing the risk
of intravascular coagulation1
• preserves leukocyte in­
tegrity thereby helping to main­
tain the pulmonary architecture1
soiu-Medroi
helps reduce 
pulmonary 
damage 
and increase 
survival rates
The recovery of patients in shock 
is often complicated by a pattern of 
deteriorating pulmonary function. 
This pulmonary insufficiency pro­
gresses despite restoration of haemo­
dynamic balance and apparent stabili­
zation of the acute episode.
Under conditions of prolonged shock, 
lack of oxygen at the cellular level 
causes alterations in the oxygen-carbon 
dioxide exchange mechanism. These 
changes in cell metabolism lead ultimately 
to interstitial cedema and perivascular 
haemorrhage.1 Polymorphonuclear leuko­
cytes aggregate in the pulmonary capillaries 
and obstruct the pulmonary vascular bed. 
As these trapped cells break down, they 
release lysosomes, tiny subcellular par­
ticles containing proteolytic enzymes.1 
These enzymes attack their host cell and 
go on to dapiage or destroy other cells.2 
The resulting tissue damage may not 
readily repair itself even if the shock 
patient survives.
When administered in conjunction 
with standard therapeutic measures, 
Solu-Medrol exerts a protective 
effect on the lung and improves 
the patient’s chance 
of survival.
Prescribing information 
on following page
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In the treatment 
of shock and its 
pulmonary 
complications
solu-Medroi
soon enough, 
often enough, 
in pharmacologic 
doses
Dosage and Administration:
In treating severe shock, there is a tendency 
in current medical practice to use massive 
(pharmacologic) doses of corticosteroids. (The 
anti-inflammatory activity of 1 mg of Solu- 
Medrol is equal to 4 mg or more of hydrocor­
tisone.)
The suggested dosage of Solu-Medrol for se­
vere shock is 30 mg/kg stat and repeated in 
four hours, if necessary.
Therapy is initiated by administering Solu- 
Medrol intravenously over a period of at least 
ten minutes. In general, therapy should be con­
tinued only until the patient’s condition has 
stabilized-usually not beyond 48 to 72 hours. 
Solu-Medrol may be given by intravenous in­
jection, by intravenous infusion, or by intra­
muscular injection. The preferred method for 
initial emergency use is intravenous injection. 
Cautions: The general precautions and con­
traindications to systemic corticosteroid ther­
apy should apply to the use of Solu-Medrol. 
However, when used for medical emergencies, 
or in shock-like states, the possible lifesaving 
effects must be weighed against the possible 
undesired hormonal effects. In the treatment 
of shock, Solu-Medrol should be adjunctive to 
conventional supportive therapy such as fluid 
replacement, etc. Although adverse effects 
associated with high-dose short-term corti- 
coid therapy are uncommon, peptic ulceration 
may occur.
Supplied: In Mix-O-Vials containing Medrol 
(as methylprednisolone sodium succinate), 40 
mg, 125 mg, 500 mg, and 1 g vials with water 
for injection.
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CRITIQUE OF ITEM 317 (SESAP II)
The polyglycolic acid suture has been de­
veloped to bridge the gap between the ab­
sorbable and nonabsorbable sutures. It is 
very strong for its size, slips through tissue 
smoothly, and degenerates by hydrolysis 
without leaving a residue of inflammatory 
elements. Gut sutures fragment and are 
lysed by enzymatic action. The presence of 
infection does not increase the rapidity of 
hydrolysis.
Further use of polyglycolic acid must be 
evaluated, but it has, to date, received 
favorable comment.
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